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Abstract

EFFECT OF A YOGURT INTERVENTION ON ADIPOSITY AND METABOLIC
OUTCOMES IN WOMEN
Eryn Boyet
Dissertation Chair: Barbara K. Haas, Ph.D.
The University of Texas at Tyler
December 2016
Over 40% of women in the United States are obese. The Strategic Plan for NIH
Obesity Research focuses on “ways to hasten the translation of research evidence from
discovery to intervention.” The Strategic Plan also calls on investigators to look at
influential points in the lifespan which may affect obesity. Few interventional studies on
obesity in women during the perimenopausal time period have been completed. Research
in broader populations suggests increased dairy, particularly full-fat products, may
decrease central adiposity and improve metabolic indicators of diabetes and
cardiovascular disease. The objective of this study was to investigate the effects of dairy
yogurt intake in women on body composition and factors related to metabolism and
adiposity. Women (n=59) were randomly assigned to either a full-fat yogurt, non-fat
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yogurt, or a control group. Demographic data, health behaviors, anthropometric measures
(Blood Pressure (BP), Body Mass Index (BMI), waist/hip circumference, body fat %),
and metabolic indicators (glucose, insulin, cortisol, and lipid panels) were assessed.
Forty-seven (n=47) women completed the 12-week study. There were no significant
differences between changes in body weight, body composition, or metabolic indicators
in the yogurt or control groups. There was a favorable decrease in systolic, F (2,
46)=10.06, p<.001 and Diastolic F(2, 46)=6.847, p=.003, blood pressures in the full-fat
yogurt group. This study gives no clear support to the hypothesis that intakes of yogurt
beneficially affects aspects of adiposity or metabolism. The positive effects on blood
pressure with consumption of full fat yogurt suggest a possible relation to effects on the
vasculature.
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Chapter 1
Introduction and General Information
Obesity Concerns
According to the Center for Disease Control (CDC) over 70% of adult US (>20
years old) men and women were overweight in 2013-2014; of these over 37% were obese
(Center for Disease Control, 2016). Obesity is known to play a critical role in the
morbidity and mortality of many cardiovascular and metabolic diseases in adults (Kaur,
Sharma, & Singh, 2015; Kazuhiro et al., 2014; Mantatzis et al., 2014; Park et al., 2013).
From 1980 through 2014, the number of Americans with diagnosed diabetes has
increased fourfold (from 5.5 million to 22.0 million) (Center for Disease Control, 2015).
Likewise, in 2014-2015, an estimated 27 million people had heart disease and 6.3 million
incurred a cerebrovascular accident. Additionally, over 24% of the adult population had
hypertension, and 12% were battling hyperlipidemia (Center for Disease Control, 2016).
Women are not immune to these statistics, as 11% of the US population of adult women
were diagnosed with diabetes between 2011 to 2014, and close to 10% of adult women
had some form of cardiovascular disease (coronary heart disease, hypertension, stroke) in
2014 (Center for Disease Control, 2014).
In 2011, a taskforce for the National Institutes of Health (NIH) created the
Strategic Plan for NIH Obesity Research (National Institutes of Health, 2011). The
purpose of this plan was to motivate researchers to undertake projects aimed at
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interventional discoveries in obesity treatments. Additionally, one purpose of this plan
was to focus on particular critical time periods or points in life which may play a role in
the development of obesity. Childhood, pregnancy, or perimenopause may be some
examples of such time points in a women’s life that may play a role in the risk
development. These time points and their relationship to the increase in, or future
development of obesity have been understudied. The goal of this program of research has
been to help close these gaps of knowledge.
Women’s Health/Perimenopause
Over 40% of adult US women (>20 years old) were obese in 2013-2014 (Center
for Disease Control, 2016). In 2010, approximately 118 million US women were over 20
years old and potentially faced the challenges associated with increased adiposity or
obesity (Census.gov, 2010). Signs of increased risk such as increased abdominal
adiposity during critical time points (childhood, adolescence, perimenopause) have
received much less research attention (Davis et al., 2012; Dasgupta et al., 2012; Jull et al.,
2014; Pimenta, Maroco, Ramos, & Leal, 2014; Sutton et al., 2010).
Perimenopause is typically defined as the time between onset of menstrual
irregularity and complete cessation of menstruation. Hormonal changes (namely
declining estrogen and progesterone) during the transition may be associated with
worsening changes in adiposity. Studies show a relationship between visceral fat
accumulations with declining estrogen levels (Nicola et al., 2012). Of note, these changes
of increased body fat during this time have been seen independent of the aging process
(Datspuga et al., 2012). Inquiry into these relationships and this critical time period for
women are still being investigated by multiple interdisciplinary groups.
2

Dairy Effects
Emerging evidence suggests an inverse relationship between dairy consumption
and reduced measures of adiposity in adult populations (Bhurosy & Jeewon, 2013;
Faghih, Abadi, Hedayati & Kimiager, 2011, Jones et al., 2013; Josse, Atkinson,
Tarnopolsky & Phillips, 2011; Holmberg & Thelin, 2013; Murphy et al., 2013; Satija et
al., 2013; Wang et al., 2014; Zemel et al., 2005). Additionally, new findings suggest fullfat dairy may have a more influential effect than non- or low-fat products; those who
consume whole fat dairy may have significant lower odds of being obese (Crichton &
Alkerwi, 2014). This is demonstrated by Danish women who consumed less butter and
full fat dairy products in their diet and were more likely to have increased waist
circumferences (Halkjaer, Tjonneland, Overvad, & Sorenson, 2009).
Investigations of dairy consumption related to weight, BMI, and body
composition with mixed results have been published over the past few years (Bhurosy &
Jeewon, 2013; Crichton & Alkerwi, 2014; Faghih et al., 2011, Halkjaer et al., 2009;
Holmberg & Thelin, 2013; Jones et al., 2013; Martinez et al., 2014; Murphy et al., 2013;
Satija et al, 2013; Wang et al., 2014). Unfortunately, most research related to dairy and
obesity measures has been prospective or observational, with very few interventional
studies. Even fewer of these studies have focused solely on women. Of the few studies
utilizing experimental designs, several demonstrated significant findings when using
dairy as an intervention for reducing adiposity and improving metabolic measures in
specific populations. Josse et al. (2011) found increased consumption of dairy foods in
premenopausal obese women helped promote fat mass loss while on a diet and exercise
weight loss program. Similarly, men and women who consumed yogurt during energy
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restriction lost 81% more trunk fat than those on the control diet (Zemel, 2005). Faghih et
al. (2011) found significant decreases in waist circumference in obese women who
consumed high doses of dairy in their experimental study (Faghih et al., 2011). These
findings promote the need for further inquiry into these complex dairy-adiposity
relationships.
Research has also identified a beneficial role of dairy on other metabolic markers
and blood pressure (Josse et al., 2011; Nestel et al., 2013; Van Meijl & Mensink, 2013).
Wang, Livingston, Fox, Meigs, & Jacques (2013) found yogurt consumption was
associated with lower levels of circulating triglycerides, and glucose, lower systolic blood
pressure, and decreased insulin resistance in American adults.
Yogurt
Very few studies have specifically utilized yogurt as a dietary intervention.
However, yogurt may reduce the risk of becoming obese in adult populations (Austep,
2014; Martinez et al., 2014; Murphy et al., 2013; Wang, Livingston, Fox, Meigs, &
Jacques, 2013; Zemel et al., 2005.) Martinez et al. (2014) found yogurt consumption was
inversely associated with the incidence of obesity, while Wang, Fox, Troy, Mckeown, &
Jaques (2015) found each serving of yogurt was associated with a 6% reduced risk of
incident hypertension. Although few experimental yogurt studies have been completed, a
flagship research project in 2005 utilizing obese male and female adults found an
intervention of yogurt yielded significant results for a reduction in waist circumference
(Zemel et al., 2005). Since then further research on yogurt has been emerging in the
literature, but further investigations of the relationship of dairy to adiposity are warranted.

4

Program of Research
The program of research reported in this portfolio focuses on the health issues
associated with perimenopause and examines the effectiveness of yogurt consumption on
metabolic outcomes in women. This program of research began with an exploration of
the common concerns incurred during the critical time period of perimenopause. Results
from this review are reported in Chapter Two in the manuscript titled Current Treatment
options for the Menopausal Transition: A Brief Review. This manuscript is currently in
revision to resubmit to the Journal of Midwifery and Women’s Health, per request of the
reviewers. Findings from this review led to the identification and discussion of potential
contributors of cardiovascular and metabolic risks in women at a certain time in the
lifespan.
Although emerging research on the perimenopause experience in general is
increasing, very few researchers have investigated the complicated relationships between
this time period, increase in adiposity, and risk factors for disease. Even fewer nutritional
interventions have been assessed. In response to this gap in knowledge, a grant proposal
was submitted to the Southern Nursing Research Society in spring 2015. A copy of the
proposal is included in Chapter Three. While scored, but not funded, the grant
application served as the basis for an interventional study, reported in Chapter Four. This
manuscript, titled Effect of Dairy Consumption on Adiposity and Metabolic Outcomes in
Women¸ reports the results of that study.
Prior to study initiation, The University of Texas at Tyler’s Institutional Review
Board (IRB) approval was secured for implementation of a randomized clinical trial to
address this need of increased interventional studies (Appendix A). Recruitment
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challenges led to a subsequent increase in scope to include all adult women meeting
inclusion criteria. The IRB approval of the modification is found in Appendix B.
Protection of the rights of the participants in this project was upheld through a variety of
measures implemented to ensure safety, privacy, and confidentiality for all of those
involved. Procedures evaluating the health status of all participants at baseline were
documented. Safety issues related to diet, allergies, and potential drug and disease
interactions with the intervention were also assessed. Those with disclosed dairy allergy,
lactose intolerance, or certain enzyme deficiencies were excluded. Prior to signing the
informed consent, full disclosure of the study’s general purpose, benefits, risks,
participants’ rights, and responsibilities was discussed with all participants. Regulations
for the Health Insurance Portability and Accountability Act (HIPAA) for protected health
information was maintained at all times. Participants were notified that they could have
terminated participation at any time for any reason without penalty. Data was stored on a
password protected computer supplied to the researcher by the University of Texas at
Tyler. Selection of confidential facilities when collecting sensitive data was maintained at
all times. Also, results are being disseminated as aggregate data, with no identification of
individual participants.
This study’s aim was to examine the relationships between yogurt intake and
measures of adiposity and metabolic outcomes in perimenopausal women. Participants
were invited to participate via a recruitment flyer (Appendix C) and letters sent to
patients served by an obstetrics and gynecology office (Appendix D). Following
informed consent (Appendix E) and HIPAA consent (Appendix F), participants
completed a demographic survey (Appendix G), report of dairy consumption (Appendix
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H), and kept a log of dairy intake (Appendices I and J). Acceptability of the intervention
was assessed at the end of the study (Appendix K). Results from this study are reported in
Chapter Four. Findings from this research provide clinical data to help guide further
inquiry of the complex relationships between nutrition, metabolism, health disease risk,
and critical time periods in a woman’s life. A summary of this program of research, along
with recommendations for practice and research, are discussed in Chapter Five.
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Chapter 2
Current Treatment options for the Menopausal Transition: A Brief Review
Abstract
The menopause transition is marked by a period of erratic and declining sex
hormones which potentially result in a variety of physical and emotional concerns in
middle aged women. Some women are asymptomatic while others report severely
debilitating complaints. Mainstream hormonal treatment options vary in safety and
efficacy. Millions are spent every year by perimenopausal women to treat their
symptoms. A multitude of disciplines are eagerly seeking answers to help this population.
Despite these efforts much still remains in question for healthcare practitioners on how to
best handle this transitional period. Non-hormonal options are beginning to emerge with
some support from the Food and Drug Administration. A multi-disciplinary approach,
and further research investigation is needed. The following will review current treatment
options for some of the most commonly reported perimenopausal symptoms.
Keywords: menopause, perimenopause, hormone replacement, symptoms, safety
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Current Treatment options for the Menopausal Transition: A Brief Review
The menopause transition is typically defined as the time between onset of
menstrual irregularity and complete cessation of menstruation. There is increasing
evidence that lifestyle, socioeconomic status, body mass index, mood, climate, and
beliefs and attitudes towards menopause might explain the cultural variations in reported
symptoms. Reproductive aging can span many years typically in a woman’s 40-50’s
(O’Neil & Eden, 2012). A review of the current literature was performed utilizing the
CINAHL Complete, Health Source, and MEDLINE databases. The following search
terms were used: menopause, perimenopause, transition, hormone, non-hormonal,
alternative, vasomotor, symptoms, sexuality, depression, and obesity. Only peer reviewed
journal articles written in English were included. With the exception of the Women’s
Health Initiative (WHI) published in 2002, all other studies reviewed were less than 5
years old. Twelve original research studies and seven reviews were used. The following
material will briefly review common symptoms and treatment options for perimenopause
with discussion related to safety and efficacy.
A Review of Common Symptoms
Vasomotor Symptoms (VMS). The most common menopause transition
complaints are related to thermoregulation—hot flushes/flashes and night sweats. Studies
show 87% of women who report hot flashes experience them on a daily basis (O’Neil &
Eden, 2012). The hot flash episodes vary in duration and may be associated with
clamminess, anxiety, and palpitations. The median age of symptom onset is 51 and
9

typically lasts 1–6 years, but can persist longer than 15 years in some women (O’Neil &
Eden, 2012).
The pathophysiology of the hot flash remains unknown. Disturbed
thermoregulation appears to be related to changes in hypothalamic activity. Reduced
estrogen levels are thought to effect endorphins causing changes in norepinephrine and
serotonin levels (Huntley, 2011). The rise in core body temperature is not well
understood, but changes in estrogen alone are not believed to account for vasomotor
symptoms (O’Neil & Eden, 2012). Also, there appears to be a correlation with pulsations
of luteinizing hormone and the onset of the hot flash, although a direct cause and effect
has been disproven, so much still remains unclear on causation of poor regulation of
temperature (O’Neil & Eden, 2012).
Urogenital Effects and Sexual Functioning. Vaginal dryness, dyspareunia,
reduced libido and arousal, and difficulty achieving orgasm increases through
perimenopause and is associated with declining estrogen (O’Neil & Eden, 2012;
Abernethy, 2013). Decreased vaginal secretions, irritation, decreased vaginal elasticity,
decreased blood flow, and thinning vaginal walls are the result of declining circulating
estrogen levels at menopause (Abernethy, 2013). These events, in turn, can lead to an
increase in vaginal and urinary infections as well as decreases in sexual satisfaction.
Weight Gain and Increased Body Fat. Hormonal changes in the transition are
associated with an increase in total and abdominal fat which adds risk of cardiovascular
and metabolic disease, as well as affects quality of life. Studies show a relationship
between visceral fat accumulations with declining estrogen levels (Nicola et al., 2012).
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Other researchers have found perimenopause increased body fat mass and central
adiposity, independent of age (Datspuga et al., 2012).
Cognitive Decline. A long-standing, yet unconfirmed hypothesis is that cognitive
difﬁculties occur as a result of declining estrogen. Estrogen promotes neuronal growth
and survival and acts on the cholinergic system, which is linked to cognitive
functioning/memory. Many report forgetfulness and concentration difficulties during
perimenopause, but further investigation is needed.
The Study of Women's Health across the Nation (SWAN) which was a 6-year
epidemiologic research project, explained that perimenopausal women did not show the
expected improvements in verbal memory and processing speed that pre- and
postmenopausal women did (Greendale et al., 2010). In addition, they looked at whether
depression, anxiety, sleep, and VMS affected cognitive performance/processing speed
and found the variables did not account for the transient decrement in the learning
observed during late perimenopause (Greendale et al., 2010). Other investigators
attempted to compare pre, peri, and postmenopausal women in cognitive measures and
found postmenopausal women performed significantly worse than pre- and
perimenopausal women on delayed verbal memory tasks, and significantly worse than
perimenopausal women on phonemic verbal fluency tasks (Webber, Maki, &
McDermott, 2014) demonstrating conflicting results.
The interplay between other components such as age, mood, and sleep disturbance, make
the “cognitive decline” variable difficult to assess. In addition, it is possible that other life
factors during this time period may influence stress and cognitive function in ways
independent of hormonal fluctuations.
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Other Physical Symptoms. Most evidence suggest sleep disturbance increases
significantly in middle-aged women. The relationship between self-reported sleep
problems and the menopause transition have inconsistent results (O’Neil & Eden, 2012;
Tom, Kuh, Guralnik, & Mishra, 2010). There is question if sleep disturbance is
independent of night sweats and hot flashes. Also, a somewhat less studied symptom of
perimenopause includes migraine headaches. Estrogen withdrawal is a recognized trigger
and has been associated with worsening migraines in perimenopausal women
(MacGregor, 2012).
Emotional Symptoms. Estrogen has a role in neurotransmission involved in
depression. Many theories suggest estrogen acts as a serotonergic agonist by increasing
receptor binding sites, synthesis and uptake (Simon et al., 2013). Symptoms of depression
may be attributed to factors other than just changing hormone level. Hot flashes/night
sweats, insomnia, lifestyle, feelings for a partner, marital status, and interpersonal stress
may significantly affect mood during the menopause transition. Cross-sectional studies
consistently report the highest prevalence of depression occurs in women during
reproductive years, but longitudinal studies during perimenopause have demonstrated
conflicting results (Bromberger et al., 2011; Judd, Hickey, & Bryant, 2014; Soares &
Frey, 2010).
The risk of major depression may be greater for women during perimenopause
compared to those who are pre-menopausal (Judd, Hickey, & Bryant, 2014). Mood
changes are reported more often in Caucasian women and some concede that several
biological and environmental factors seem to be independent predictors (Bromberger et
al., 2011; O’Neil & Eden, 2012). In a recent literature review of 23 population based
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studies, authors looked for evidence to support the idea that depression was the result of a
biological response to hormone changes, but they found no proof to support this (Soares
& Frey, 2010).
Existing and Emerging Practice: Treatment Options
Hormone Replacement. Hormone replacement therapy (HRT) is frequently used
for symptoms associated with estrogen withdrawal (O’Neil & Eden, 2012). Although
most commonly prescribed for vasomotor symptoms, new studies suggest HRT may
partly prevent deleterious body composition changes, namely visceral fat (Nicola et al.,
2012). HRT may also be helpful for estrogen withdrawal migraines (MacGregor, 2012)
and is effective in preventing bone loss (O’Neil & Eden, 2012). Since bone protection
decreases after cessation of therapy, the long-term use remains controversial (O’Neil &
Eden, 2012). HRT use declined some as a result of the Women’s Health Initiative (WHI)
(Rossouw et al., 2002). This study was intended to define risks and benefits related to the
incidence of heart disease, breast/colorectal cancer, and fractures in postmenopausal
women aged 50–79 years. Investigators concluded the, “overall health risks exceeded
benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up
among healthy postmenopausal US women” (Rossouw et al., 2002).
One common misconception is that WHI data should be extrapolated to the
perimenopausal population. The potential benefits of HRT initiated during the
perimenopause was not evaluated in the WHI as the population was mostly asymptomatic
postmenopausal women. Hypotheses suggest endogenous sex steroids may be
cardioprotective but the same theory using HRT has produced conflicting results.
Findings of the WHI suggested a helpful effect in younger postmenopausal women but an
13

increased risk of heart disease/clots in older postmenopausal women (O’Neil & Eden,
2012). Contraindications to estrogen therapy include: history of female cancers, blood
clots, cerebrovascular or heart disease, and liver dysfunction, among others.
It should also be noted, “bioidentical hormones,” refers to hormones that are
identical on a molecular level with endogenous hormones but are individually
compounded by some pharmacies (Moriea, Silva, Santos, & Sarado, 2014) Marketing
strategies claim these are more “natural,” and efficacious than synthetic forms, but this is
not supported by clinical evidence and their purity and risks are not known (O’Neil &
Eden, 2012). For now, it is widely assumed by experts that benefits and adverse effects
are likely similar to synthetic forms of HRT, although further investigation is warranted
(Huntley, 2011).
Non-Hormonal Therapies and Interventions. SSRI/SNRI. Selective serotonin
reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs)
have been marketed for off label use to treat VMS and are gaining popularity. Some
suggest these drugs should be first line therapy for depression in perimenopause (Soares
& Frey, 2010) while others feel adjuvant use with estradiol may be best for treatment
of depression and VMS (Bromberger et al., 2011). Although higher doses of paroxetine
have long been used to treat depressive and anxiety symptoms in general populations, the
lower dose (Brisdelle) has only been approved for VMS (Simon et al., 2013). Fluoxetine
(Prozac) and venlafaxine (Effexor) have been used for many years in perimenopausal
women, but are not currently FDA approved. These drugs may also be helpful for treating
migraines as well (MacGregor, 2012).
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Anti-epileptic. Several random controlled trials show gabapentin demonstrated
consistent and statistically significant benefits over placebo for VMS. Despite
investigational uses for over a decade, the first largely publicized research emerged in
2012 under the phase 3 clinical trial known as BREEZE 3. Researchers studied 600
postmenopausal women to test extended-release gabapentin (Serada, Depomed) for
effects on sleep and hot flashes in menopausal women (Lowry, 2012). The trial showed
gabapentin significantly reduced the average frequency and severity of hot flashes at 4
and 12 weeks of therapy compared to placebo (Lowry, 2012). Sleep was measured using
both the Insomnia Severity Index (ISI) score and the Daily Sleep Interference (S/I) score.
There were clinically meaningful reductions in the gabapentin group, compared with the
placebo group (Simon et al., 2013).
Unfortunately, not all experts agreed with the significance of the BREEZE study
findings. Several members of an advisory panel for the FDA strongly opposed approval
of the drug, suggesting the effects were only marginal and did not justify the risks. In
2013, the FDA rejected the approval for gabapentin in menopause, claiming the drug
failed to show superiority to the placebo. Interestingly, this same advisory panel also
rejected their support of the low dose paroxetine (Brisdelle), but the FDA ended up still
approving it in 2013.
SERM. The “pink pill” or “Viagra for women” was coined in 2013 when the
FDA approved ospemifene (Osphena), a selective estrogen receptor modulator (SERM)
which acts similarly to estrogen on the vaginal epithelium, building vaginal wall
thickness. SERM’s are synthetic non-steroidal agents which have varying estrogen
agonist and antagonist activities in different tissues. Ospemifene aims to reduce
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dyspareunia in menopausal women. Although approved, some experts are concerned
about long term adverse effects of ospemifene on other body systems.
TSEC. A new class of drug combination currently under clinical trial is the tissue
selective estrogen complexes (TSEC’s), which combine estrogen with a SERM. It is
believed that different changes in the ER receptors may occur with different complexes
or combinations of drugs. Therefore the drug could be utilized for either agonist or
antagonist effects in their corresponding targeted tissues. Thus far, only bazedoxifene
(combined with conjugated equine estrogen) has shown to be safe and effective in early
testing. This particular combination has shown relief of menopausal hot flashes, vaginal
atrophy, and prevention of bone loss without stimulation of the breast or uterus. Due to
its anti-proliferative effect on the uterus, progesterone would not need to be added
(Pinkerton & Thomas, 2014).
Complementary and Alternative Medicine. The use of complementary or
alternative medicine (CAM) is high in perimenopause. The concern is lack of regulation
and little evidence to support their efficacy or safety. A systematic review of the
prevalence of CAM usage showed the average 12-month prevalence of use was 47.7%
(Posadzki et al., 2013). Also, 55% of women studied did not disclose their use of CAM to
their healthcare professional. Herbal medicine, followed by soy/phytoestrogens, evening
of primrose oil, relaxation, and yoga were the most common in the review (Posadzki et
al., 2013).
Phytoestrogens are plant-derived estrogens often sold over the counter with
effects that vary according to plant species. Soy isoflavones and red clover have shown
inconsistent results for effects on VMS (Crawford et al., 2013). Moriea, Silva, Santos, &
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Sardao (2014) state in a recent review that phytoestrogens “have structural similarities to
estradiol, interacting with cell proteins and organelles, presenting several advantages and
disadvantages versus traditional HRT in the context of menopause.”
Black cohosh, which has no estrogenic effects, may help decrease vasomotor
complaints by increasing dopamine and serotonin activity of the hypothalamus. However,
in controlled trials the evidence is conflicting and there are concerns regarding liver
toxicity (O’Neil & Eden, 2012). Although several other complementary options have
been investigated (vitamin E, evening of primrose, wild yam, ginseng, and others)
research on soy, red clover, and black cohosh have been the most prominent in the
literature. Despite occasionally producing promising results, most of these products still
lack evidence for efficacy for menopausal symptoms.
Calcium and Vitamin D. Both calcium and vitamin D supplement use among
women is controversial. Necessary for the maintenance of bone health, calcium may also
play a role in weight loss, hypertension, and a variety of cancers. The Institute of
Medicine (2010) currently recommends 1,200 mg of calcium per day, for women 51
years and older to reduce risk of osteoporosis. Declining estrogen is associated with
impaired intestinal calcium absorption. Vitamin D levels and obesity have been heavily
investigated, with more research of perimenopausal populations emerging (Truesdell,
Shin, Liu, & Ilich, 2011). Mixed opinions exist between relationships of calcium, soy
protein, isoflavones, bone metabolism, sarcopenia, and adiposity. Little research has been
performed on the relationship between vitamin D/calcium and other common symptoms
of perimenopause.
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Diet, Yoga, and Exercise. Diets of cyclic weight loss and gain are common in
women and are especially harmful in perimenopause, as weight loss occurs more often
from muscle loss. Promotion of a diet high in nutrient density and lower in energy density
is promoted by experts (Haimov-Kochman, Constantini, Brzezinsk, & HochnerCelnikier, 2013) Also, mind–body, self-relaxation, and paced breathing has shown a
reduction in severity and frequency of vasomotor symptoms in some small studies
(O’Neil & Eden, 2012).
No specific perimenopause exercise regimen has been recommended by experts,
however a recent study indicated the higher frequency of exercise (aerobic and nonaerobic), the lower severity of climacteric symptoms (Haimov-Kochman, Constantini,
Brzezinsk, & Hochner-Celnikier, 2013). These findings contradict a recent review from
Stojanovska, Apostolopoulous, Polman, and Borkoles (2014) who concluded there is
“insufficient evidence demonstrating that exercise was effective in treating vasomotor
menopausal symptoms, and, it was not clear whether exercise was more beneficial
compared to HRT or yoga.” Furthermore, in an arm of the SWAN study, authors suggest
acute increases in physical activity were actually associated with increased hot flashes
without physiologic justification (Gibson, Matthews, & Thurston, 2014).
Conclusions
Healthcare providers of women likely feel perplexed about the current body of
scientific literature. Menopausal symptoms are poorly understood combinations of
genetic, psychological, and environmental factors. There is not only discrepancy between
objectifying symptoms, but more importantly, what to actually do about them. In
addition, some symptoms mimic other potentially age related concerns which makes
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them difficult to assess independently. Reliable treatments have controversial safety
profiles. Women are living longer and most will go through the menopause transition at
some point. A team approach is best to tackle all of the health issues of this population.
Individually tailored care plans may be needed to address symptom relief verses
health risks. A table was developed to highlight the efficacy of currently marketed
interventions (see Table 1). Thankfully, the interdisciplinary approach allows experts in
the fields of endocrinology, gynecology, orthopedics, nutrition, psychiatry, and many
others to contribute to the gaps of knowledge collectively. The WHI provided a wealth of
information for the health of postmenopausal women. However, it also created fear of
HRT which in turn has led to investigation of other options. Larger random controlled
trials should be performed on the safety, efficacy, and side effects of non-hormonal
therapies being utilized. With the widespread, and poorly regulated distribution of some
of these substances, the potential for long term safety is concerning.
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Table 1. Current Interventions for Perimenopausal Symptoms
Intervention Category

VMS

Depression/

Sleep
Disturbance

Mood

Weight Gain/
Abdominal Fat

Vaginal

Reference

Symptoms

O’Neil
(2012)
Rossouw
(2002)

Hormonal

Sufficient

Sufficient

Sufficient

Sufficient

Sufficient

SSRI/NRSI

Sufficient

Sufficient

Inadequate

Not Suggestive

Not Suggestive Soares
(2010)
Simon
(2013)

Gabapentin
(Serada,
Depomed)

AntiEpileptic

Sufficient

Not Suggestive

Suggestive

Not Suggestive

Not Suggestive Lowry
(2012)

Ospemifene
(Osphena)

SERM

Not Suggestive Not Suggestive

Not Suggestive Not Suggestive

Sufficient

Inadequate

Suggestive

Not Suggestive Posadzki
(2013)
Crawford
(2013)
Moriea
(2014)
Not Suggestive Truesdell
(2011)

HRT
estrogen/
progesterone
Paroxetine
(Brisdelle)
Venlafaxine
(Effexor)

Soy Extracts, Herbal/
Yams Black Isoflavone
Cohosh, Red
Clover

Calcium and
Vitamin D

Mineral

Exercise and Physical

Not Suggestive

Not Suggestive

Not Suggestive Not Suggestive

Not Suggestive Suggestive

Inadequate

Inadequate

Inadequate

Sufficient

Suggestive

Yoga

Level of Evidence:
1. Evidence is sufficient to infer a causal relationship.
2. Evidence is suggestive but not sufficient to infer a causal relationship.
3. Evidence is inadequate to infer the presence or absence of a causal relationship
(evidence is sparse, poor quality, conflicting).
4. Evidence is not suggestive of a causal relationship.
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Pinkerton
(2014)

Haimov
(2013)
Stojanovska
(2014)
Gibson
(2014)
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Chapter 3
Effect of Dairy Consumption on Adiposity and Metabolic Outcomes in Perimenopausal
Women
Southern Nursing Research Society Grant Submission Proposal
Abstract
Nearly 71% of U.S. women aged 40-59 are at risk for diabetes and cardiovascular
disease due to increased obesity. The Strategic Plan for NIH Obesity Research suggests
identifying factors unique to a specific point in the lifespan to guide obesity interventions.
One of these critical time periods, perimenopause, has been understudied. Hot flashes and
night sweats are familiar perimenopause complaints; symptoms such as increased central
adiposity and decreased ability to maintain a healthy weight have received less attention.
Research in other populations suggests increased dairy, particularly full-fat, may decrease
central adiposity and improve metabolic indicators of diabetes and cardiovascular
disease.
Guided by the Integrated Theory of Health Behavior Change, a randomized
controlled trial will determine the effect of a dietary intervention on adiposity and
metabolic outcomes in perimenopausal women. Participants will be randomly assigned to
either a full-fat yogurt, non-fat yogurt, or a control group. Demographic data, health
behavior practices, anthropometric measures (BMI, waist and hip circumference), and
metabolic indicators (glucose, lipid panels, vitamin D levels) will be assessed before and
after the 12-week intervention. Yogurt consumption will be documented in a food diary.
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Outcomes will be evaluated using MANOVA. A post-study survey will assess feasibility
of the intervention.
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Effect of Dairy Consumption on Adiposity and Metabolic Outcomes in Perimenopausal
Women
Objectives and Specific Aims
The objective of this feasibility study is to improve the nutritional and metabolic
health of perimenopausal women. Specific aims include:
Aim 1: Determine the effect of full-fat versus non-fat yogurt consumption on metabolic
outcomes of perimenopausal women.
Aim 2: Determine the effect of full-fat versus non-fat yogurt consumption on adiposity
outcomes of perimenopausal women.
Aim 3: Determine the feasibility of yogurt consumption as a dietary intervention for
improving metabolic and adiposity outcomes in perimenopausal women.
Background and Significance
According to the Center for Disease Control (CDC) nearly 71% of women aged
40-59 were overweight or obese in 2011-2012.1 Obesity, or adiposity, is an increasing
problem in the US (Ogden, Carroll, Kit, & Flegal, 2014). Specifically, central adiposity
plays a critical role in the morbidity and mortality associated with diabetes, metabolic
syndromes, and cardio/cerebral vascular disease in adults (Mantatzis et al., 2014; Kaur,
Sharma, & Singh, 2015; Kazuhiro et al., 2014; Park et al., 2013). A taskforce for the
National Institutes of Health (NIH) (2011) created the Strategic Plan for NIH Obesity
Research. The purpose of this plan was to “serve as a guide to accelerate a broad
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spectrum of research toward developing new and more effective approaches to address
the tremendous burden of obesity” (NIH, 2011). One way the plan broadly proposed to
do this was to “design and test interventions to promote healthy weight” (NIH, 2011). In
addition, one objective of this plan emphasizes the importance of investigating factors
related to excess weight gain during “critical periods and life events” (NIH, 2011). The
taskforce indicated identifying factors unique to a specific point in the lifespan could
provide important insights for intervention development. Perimenopause, one of these
critical time periods, has been significantly under researched.
In 2010, approximately 23 million U.S. women between the ages of 45-54
potentially faced the challenges associated with perimenopause (Census.gov., 2010).
Perimenopause, the transition to menopause, is typically defined as the time between
onset of menstrual irregularity and complete cessation of menstruation. Reproductive
ageing typically occurs in women during their 40-50’s and is marked by a period of
erratic and declining sex hormones resulting in a variety of physical and emotional issues.
Although hot flashes and night sweats are two familiar complaints of perimenopause,
other symptoms such as increased abdominal adiposity and decreased ability to maintain
a healthy weight have received much less research attention (Datspuga et al., 2012; Davis
et al., 2012; Jull et al., 2014; Pimenta, Maroco, Ramosm, & Leal, 2014; Sutton-Tyrell et
al., 2010).
Given concerns related to hormone-replacement therapy (Antoine, Ameye,
Paesmans, & Rozenberg, 2014; Hou et al., 2013; Marjoribanks, Farquhar, Roberts, &
Lethaby, 2012; Ohira et al., 2010; Sharpe et al., 2010) women are seeking safe, nonhormonal interventions to combat perimenopausal symptoms.
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One potential non-hormonal intervention for central adiposity is related to
nutritional intake. Emerging evidence suggests an inverse relationship between dairy
consumption and reduced measures of adiposity in other populations. Some researchers
have focused on the effects of dairy on overall weight and BMI, (Bhurosy & Jeewon,
2013; Jones et al., 2013; Josse, Atkinson, Tarnopolsky & Phillips, 2011), while other
have focused more on body composition (Crichton & Alkerwi, 2014; Halkjaer,
Tjønneland, Overvad, & Sørensen, 2009; Holmberg & Thelin, 2013; Murphy et al., 2013;
Satija et al., 2013; Wang et al., 2014; Zemel et al., 2005). Current literature suggests fullfat dairy may be more effective for decreasing adiposity than non or low-fat products
(Bhurosy & Jeewon, 2013; Crichton & Alkerwi, 2014; Halkjaer et al., 2009; Holmberg &
Thelin, 2013).
Most research related to dairy fat has been prospective or observational, with very
few interventional studies. Significant decreases in waist circumference in as little as
eight weeks have been seen in obese women who consumed high doses of dairy (Faghih,
Abadi, Hedayati, & Kimiagar, 2011). A review of current literature revealed that most
dietary RCT’s utilizing dairy lasted 8-16 weeks in length. Yogurt may reduce the risk of
becoming obese (Martinez-Gonzalez et al., 2014; Murphy et al., 2013; Zemel et al.,
2005). Very few experimental studies have utilized yogurt as a dietary intervention. In a
study with 34 obese adults ages 18-50, an intervention of yogurt yielded significant
results for waist circumference reduction (0.42 p<.005) and fat loss (0.52 p<.005).28
Limited studies show beneficial findings when yogurt is used as an intervention for
reducing adiposity in adults (Martinez-Gonzalez et al., 2014; Wang, Livingston, Fox,
Meigs, & Jacques; 2013).; Zemel et al., 2005). In addition, some research on the
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beneficial role of dairy on metabolic markers and blood pressure has been identified in
other populations (Austep, A, 2014; Josse, Atkinson, Tarnopolsky, & Phillips, 2011;
Nestel et al., 2013; Van Meijl & Mensink, 2013; Wang et al., 2013). Specifically, the
role of yogurt consumption on pertinent metabolic markers in perimenopausal women
have not been well studied and is still unknown. The proposed study will address these
gaps in the science.
Research Design
Guided by the Integrated Theory of Health Behavior Change (ITHBC) (depicted
in Table 1 of Chapter Four), an experimental design will be utilized to address the study
aims. The ITHBC was developed to “increase a person's ability to engage in behavior
change to increase his/her self-management behavior” (Ryan, 2009). The ITHBC
contributes to better understanding of health behavior by integrating knowledge and
beliefs, self-regulation, and social facilitation. The concepts from the ITHBC were used
to develop an intervention related to the prevention or reduction of adiposity and
improvement of metabolic outcomes in perimenopausal women.
Sample/Subjects
The accessible population for this study is adult perimenopausal women living in
North Texas. The study will take place in a private women’s health clinic in North Texas.
The practice sees approximately 80-100 women each month for well women visits
suggesting recruitment could be completed within three months. Since perimenopause
relates to the beginning of hormonal changes leading up to the complete cessation of
menstruation, the Stages of Reproductive Aging Workshop (STRAW) staging system
(see figure 1) will be used to determine perimenopausal status (Harlow, 2012). According
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to the STRAW definition, menstrual irregularity is described as, “the onset of menstrual
cycle length variability with a persistent difference of 7 days or more in the length of
consecutive cycles, with the persistence being defined as at least one recurrence within 10
cycles of the first variable length cycle” (Harlow, 2012).
Inclusion criteria will include: (a) perimenopausal status as defined by STRAW
criteria (b) women who are at least 40 years old and (c) those who are able to read, speak,
and write English. Exclusion criteria will include women with: (a) diagnosis or currently
taking medication for diabetes or hyperlipidemia, (b) lactose intolerance, (c) allergy to
dairy products (d) those who have had a greater than 20 pound weight change in the past
year, or (e) women who have had a hysterectomy or oophorectomy. Women taking
hormone replacement therapy (HRT) will be included as the effects of the nutritional
intervention may still be effective even with low doses of HRT.

Figure 1. STRAW Menopause Transition Criteria (Harlow, 2012)
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Based on an alpha of .05, power of .80, and effect size of .35, power analysis (GPower 3.1) suggests a total sample size of 45 (15 per group) for repeated measures
MANOVA will be required. Anticipated effect size (d) was calculated based on results of
previous studies of dairy and adiposity (Crichton & Alkerwi, 2014; Josse et al., 2011;
Wang et al., 2014; Zemel et al., 2005). To account for anticipated attrition associated
with longitudinal studies, a total of 51 participants will be recruited.
Measures/Instruments
Survey Instruments. The Participant Demographic Survey (Appendix D in
Chapter Four) will be used to collect pertinent patient demographic data. Participants will
be providing dietary data about their use of yogurt by completing the 8-item Dairy Intake
Questionnaire (Appendix E in Chapter Four), Daily Yogurt Form (Appendix F in Chapter
Four), and Daily Dairy Form (Appendix G in Chapter Four). A 6-item Post Study
Feasibility Survey (Appendix H in Chapter Four) will also be used. After development,
the PI sent each of these instruments to content experts, colleagues, and others not
familiar with the research to elicit feedback on the wording and face validity. The forms
were reorganized and reworded based on feedback.
Metabolic/Physiologic. Outcomes (Aim 1) will be measured by: Blood pressure,
fasting serum glucose, serum insulin, fasting serum lipid panel (total cholesterol, low
density lipoprotein [LDL], high density lipoprotein [HDL], and triglycerides), fasting
serum vitamin D 25 OH, and free serum cortisol. Labs will be collected at the clinical site
and will be prepared, stored, and transported according to specific local clinic and lab
protocols. A single laboratory will be utilized for all blood analyses. Measurement of
blood pressure will be obtained using the equipment and instruction standards described
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in the National Health and Nutritional Examination Survey (NHANES) Blood Pressure
Procedures Manuals.
Adiposity. Outcomes (Aim 2) will be measured by: body mass index (BMI),
waist circumference (cm), hip circumference (cm), and body fat percent. Collection of
weight and height (to calculate BMI), as well as waist and hip circumferences will be
obtained using the equipment and instruction standards described in the National Health
and Nutritional Examination Survey (NHANES) Anthropometry Manuals (CDC, 2009).
The longstanding reputable history of NHANES make their manuals an appropriate
choice for this study.
Anthropometric measures predicted abdominal fat almost equally as well as
Computed Tomography (CT) or Dual energy x-ray absorptiometry (DXA) scanning in
recent study of women (Direk et al., 2013), concluding that anthropometric measures can
be reliably utilized to derive estimates of visceral fat. Although CT and DXA are
considered the gold standard for body fat percent measurement in clinical settings, due to
funding limitations and access, this tool will not be utilized for this study. A professional
grade bio-impedance scale used to determine body composition, will be used to assess
percentage of body fat. Electrical bio-impendence monitoring has been utilized in a
number of published studies as an alternative means to CT/DXA to assess total body fat
percent.
Compliance. Outcomes (Aim 3) will be assessed using the Daily Yogurt Form.
This format will enable participants to exercise control over some of the diet decisions
they make as well as promote behaviors of self-regulation, an integral concept in the
ITHBC model. This form will be utilized by participants to track the number of ounces,
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fat (grams), and brand/flavor of yogurt consumed each day. In addition, the Post Study
Feasibility Survey will be administered to assess participants’ likelihood to continue the
use of yogurt as part of their nutritional intake after the study is completed.
Methods
All participants will be interviewed in person, via phone, or email (depending on
how they contact the PI) to assess for initial inclusion into the study. Staff at the women’s
clinic will be instructed on how to inform prospective participants of the study and next
steps for contacting the researcher when interested women are identified. If inclusion
criteria are met, potential participants will be asked to meet with the PI in an initial
session in which the purpose and procedures of the study will be disclosed. After signing
an Institutional Review Board (IRB) approved consent form, participants will be
randomly assigned to one of three groups (a control group, a non-fat yogurt group, or a
full-fat yogurt group) by drawing a sealed envelope (assignment will be concealed).
Baseline demographic surveys, anthropometric measurements, and lab work will then be
obtained and entered into the participant’s electronic medical record. All data collection
will be performed in an exam room to ensure privacy. Following baseline data collection,
participants will be instructed not to make any major diet changes during the course of
the 12-week study unless instructed to do so as indicated by the group assignment. They
will also be asked not to change their activities or exercise regimens during this time.
Participants will be instructed to report any new medications, changes in
medications, or changes in health status. Participants in the full-fat and non-fat yogurt
groups will be given a Daily Yogurt Form (Appendix F in Chapter Four) to document the
amount and type of yogurt consumed each day. Participants in the control group will be
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given a comparable Daily Dairy Form (Appendix G in Chapter Four) to document all
dairy intake on a daily basis. The forms will be submitted weekly to the PI as a means to
encourage and assess compliance with the intervention. Electronic submission via email
will be recommended but postage paid options for regular mail will also be available. At
the end of the 12-weeks, anthropometric measurements and lab work will be reassessed
and again entered into the patient’s electronic medical record. In addition, the Post Study
Feasibility Survey (Appendix H in Chapter Four) will be distributed to intervention group
participants to obtain feedback on the intervention.
Intervention description. The non-fat intervention group (NF) will be asked to
consume 12 total ounces of non-fat yogurt per day for 12 weeks. The participant will be
allowed to purchase any brand, flavor, or texture of yogurt of their choice. The
participant will be instructed to consume commercial dairy milk yogurt (from cows) that
cannot exceed 150 calories, 18 grams of carbs, or 0 grams of fat (per 6 ounce serving).
They may consume the yogurt at any time each day in combination with another meal, as
a meal replacement, or as a snack. They must record the amount in ounces and
brand/flavor of yogurt consumed on the Daily Yogurt form (Appendix F in Chapter Four)
each day. The participants will be asked to consume all other dairy products in the same
amounts and frequencies as before the study and record it on the Daily Dairy Form
(Appendix G in Chapter Four).
The full-fat intervention group (FF) will be asked to consume 12 ounces of full fat
yogurt per day for 12 weeks. There will not be any upper limitations on calories, carbs, or
fat. They will be instructed to consume yogurt with at least 6 grams of fat per 6 ounce
serving. They must record the amount, total grams of fat, and brand/flavor of yogurt
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consumed on the Daily Yogurt Form (Appendix F in Chapter Four) each day. The
participants will be asked to consume other dairy products in the same amounts and
frequencies as before the study and record it on the Daily Dairy Form (Appendix G in
Chapter Four).
The control group (CG) will be asked to make no changes to their current dietary
habits. They will be instructed to complete a daily dairy intake form. Though this
heightens awareness of consuming dairy products, the emphasis is not on yogurt. The
form will serve as a means to assess typical yogurt intake within the sample.
Data Collection
Baseline demographic survey and dairy intake form, anthropometric measures,
and blood draws will be performed by the PI at baseline. Yogurt (intervention groups)
and dairy (control group) diaries will be collected every two weeks for 12 weeks.
Participants will be asked to submit the diaries either electronically to an email address
dedicated to the study or by mail using a postage paid envelope provided by the study.
Anthropometric measures and blood samples will also be collected by the PI at the
conclusion of the study, along with the post yogurt study survey. All survey data
completed on paper will be stored in a locked file in a locked office. Anthropometric
measures and lab reports will be recorded in a secure electronic medical record system
which is password protected. All study data will be transcribed into a password protected
Statistical Program for the Social Sciences (SPSS version 20.0) database for analysis.
Double entry will be utilized to assure error free data.
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Plans for Statistical Analysis
Data will be assessed for accuracy, outliers, and missing responses prior to
conducting analysis. Discrete variables will be examined for accuracy. Continuous
variable means and standard deviations will be examined for credibility and to assess for
outliers. Descriptive statistics will be calculated for each variable. For continuous
variables, range, mean, median, and standard deviation will be used. For categorical
variables, mean, frequency, and contingency tables will be used. Chi-square tests (for
nominal level data) and ANOVA (for continuous level data) will be used to compare the
distribution of the demographics of the three groups at baseline. Multivariate analysis of
variance (MANOVA) will be used to analyze the effect of yogurt consumption on
adiposity (AIM 1) and metabolic indicators (AIM 2) among groups. If significant
differences are noted, post hoc analyses will be conducted to determine where the
differences lie.
Feasibility (AIM 3) will be assessed via time required for recruitment, attrition
rate, Daily Yogurt/Dairy Intake form completion, and responses to the Post Study
Feasibility Survey. Recruitment will be calculated by determining the length (in business
days) it takes to obtain the 25th and 51st participant from the start of recruitment.
Intervention items will be reviewed by the research team to identify issues that affected
the consumption of yogurt in perimenopausal women. The PI, recruitment assistants, and
clinic staff will discuss any challenges they faced during recruitment to identify measures
to improve the process for future study.
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Limitations and Potential Difficulties
Limitations. As with any longitudinal study, attrition could be a limitation.
Oversampling will be done to allow for potential loss of participants. Utilizing one local
clinic for assessment completion could be a limitation. Other surrounding clinics in
Northeast Texas may be utilized if additional recruitment of participants is needed.
Flyers, will be posted in numerous public and private settings with potential sources of
perimenopausal-aged women (e.g. local healthcare establishments, shopping venues,
beauty salons, churches). Woman in the intervention groups may become tired of
consuming 12 ounces of yogurt every day. To address this limitation, no restrictions will
be made for the brand, flavor, or texture of yogurt chosen. No constraints on the time of
day they will eat yogurt will be mandated, which will aid in flexibility of schedule. The
potential for confounding variables, despite exclusion criteria, cannot be entirely
controlled. Since standardization of only a few (not all) nutritional parameters will be
performed, other nutritional co-variables will still exist. Exercise or energy expenditure
will not be measured or controlled. Subjects will be asked not to make any other changes
in exercise or diet during the study. Although this opens the possibility of confounding
variables, this approach also reflects a real-world approach and will help determine if
yogurt consumption is feasible without placing additional demands or restrictions on
participants. Maintaining previous behaviors mitigates the source or impact of extraneous
behaviors since the participants serve as their own controls.
The possibility of varying degree of ovarian function within the perimenopausal
status could be a confounding factor. Assessing menstrual health through STRAW
criteria will help provide some commonality for those in perimenopausal states. Some
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variability and human error is possible when obtaining anthropometric measurements.
Body composition differences, racial and ethnic differences, and clinician technique, can
all lead to discrepancy. Body composition differences and racial and ethnic differences
are addressed in baseline data. Clinician technique is addressed by using the same person,
equipment and lab to collect and analyze data will help reduce this limitation. The selfreported nature of food consumption is also a limitation. Participants may feel
inconvenienced by having to write in a daily log. This may lead to falsification or
inaccurate recall of consumption. Therefore, a simplified, user friendly form was created
to help compliance.
Potential Difficulties. One anticipated challenge is recruitment of an adequate
number of participants. To make study participation more appealing, women are being
offered free assessments of body composition and several metabolic indicators at two
time points. The major challenge in conducting this type of research is the fiscal
resources necessary to conduct the study. Women cannot be asked to pay out of pocket to
cover blood work; providers cannot be expected to provide services for free. In this study,
the PI, who is a women’s health nurse practitioner, will provide the assessments at no
cost. The lab that supports the PI’s practice has negotiated the lowest cost possible to
provide lab services and still cover expenses.
Protection of Human Subjects
Protection of the rights of the participants in this project will be upheld through a
variety of measures implemented to ensure safety, privacy, and confidentiality for all of
those involved. All procedures will be evaluated and approved by the Institutional
Review Board at the University of Texas at Tyler. Procedures evaluating the health status
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of all subjects at baseline will be documented. Safety issues related to diet, allergies, and
potential drug and disease interactions with the intervention will also be assessed. For
example, those with disclosed dairy allergy, lactose intolerance, or certain enzyme
deficiencies would be excluded. Prior to signing the informed consent, full disclosure of
the study’s general purpose, benefits, risks, participants’ rights, and responsibilities will
be discussed with all participants. Regulations for the Health Insurance Portability and
Accountability Act (HIPAA) for protected health information (PHI) will be maintained at
all times. HIPAA consents will be obtained. Participants will be notified that they may
terminate participation at any time for any reason without penalty. Selection of
facilities/rooms/privacy interventions when collecting sensitive data (such as
anthropometric measurements) will be maintained at all times. Secure record keeping of
data and storage with password access will also be utilized during the study. Results will
be disseminated as aggregate data, with no identification of individual participants.
Data Safety and Monitoring Plan
Contact information of the research team will be provided to all study participants
at the beginning of the research project. They will be instructed to notify the researcher of
any emergencies, unforeseen events, or general concerns that arise as a result of
participating in this study. If an event is reported, the researcher will promptly notify her
adviser, and co-investigators for guidance and documentation of the event in an adverse
event log. A written notification will be submitted to the IRB within 24 hours of the
reported incident.
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Appendix A: Budget Sheet
Anticipated Expenditures
Laboratory Fees
$42 @ baseline x 51 participants=$2142
$42 @ completion X 51 participants=$2142
Bio-impedance Body Composition Scale
Palm Aneroid Sphygmomanometer
Printing Costs
9 pages x $.10 x 51 (all participants)=$45.90
1 page x $.10 x 34 (Intervention participants)
$3.40
Postage for return of diaries.
$0.49x12x51=$299.88

$4284.00

$2595.00*
$50.00
$49.30

$299.88

TOTAL
Total Requested from SNRS

$7278.18
$7078.26 – 2595 = $4683.18

Budget Justifications:
Laboratory Fees: Discounted negotiated (at cost) pricing from the lab utilized at the local OBGYN clinic are as followed: Cortisol ($13.29), Vitamin D, 25 OH ($19.00), Glucose ($1.70),
Insulin ($7.00), Lipid Panel ($2.15).
*Bioimpedance Body Composition Scale: Professional Grade Bio-impedance Scales vary in
pricing with most quality models falling in the $2,000-$6000 range. The price listed here is for a
Tanita™ TBF-410 Body Composition Analyzer that includes Tanita HealthWare™ software. The
Tanita HealthWare™ provides a bridge to most electronic medical record software packages,
which sends the measurements directly to the participants EMR reducing the chance of
transcription error. The Tanita™ TBF-410GS Body Composition Analyzer calculates body fat
percent in less than ten seconds and has a column-mounted display to decrease unintentional
damage of the equipment. Price listed is based on current listing from the Tanita™ website. The
The Bodystat™ Quadscan 4000 with Microsoft™ software is also being considered and costs
around $5700. This bio-impedance scale has been utilized by numerous healthcare companies and
researchers in a variety of peer reviewed published studies with excellent reputation.
*Recognizing the cost of either of these scales exceeds that permitted by the grant, additional
funding will be sought to cover the cost of this item.
Sphygmomanometer: Equipment currently utilized at the OB-GYN office will be assessed prior
to data collection to determine that it is professional grade, correctly calibrated, and working
properly. If it is not, a sphygmomanometer will need to be purchased to record accurate blood
pressure readings.
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Appendix A: Budget Sheet Continued

Printing Costs: Participant surveys and diaries will be completed on paper. These will be printed
at a local print shop such as Kinko’s™ (or similar) for efficiency and pricing.
Postage Costs: Participant Yogurt/Dairy Intake diaries will be returned via postage paid envelope
every two weeks for participants unable or choose not to utilize email correspondence. This
would include 12 postage paid envelopes per participant (51) x $0.49 per stamp, totaling $299.88.
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Chapter 4
Effect of Dairy Consumption on Adiposity and Metabolic Outcomes in Women
Abstract
Over 40% of adult women in the United States are obese. The Strategic Plan for
NIH Obesity Research focuses on ways to improve and expedite the ways at which
research discovery develops into clinical intervention. Research in other populations
suggests increased dairy, particularly full-fat, may decrease central adiposity and improve
metabolic indicators of diabetes and cardiovascular disease. The objective of this study
was to investigate the effects of dairy yogurt intake on body composition and factors
related to metabolism and adiposity in women. Women (n=59) were randomly assigned
to either a full-fat yogurt, non-fat yogurt, or a control group. The full-fat and non-fat
groups were instructed to consume 2 servings of yogurt daily. The control group
maintained their habitual diet. Clinical measurements were completed on admission to
the study and after 12 weeks. Demographic data, health behaviors, anthropometric
measures (BMI, waist/hip circumference, body fat %), and metabolic indicators (glucose,
insulin, cortisol, and lipid panels) were assessed. Forty-seven (n=47) women completed
the 12 week study. There were no significant differences between changes in body
weight, composition, or metabolic indicators across time within the yogurt or control
groups. There was a modest favorable decrease in systolic (p<.001) and diastolic
(p<.003) blood pressure in the full-fat yogurt group. This study gives no clear support to
they hypothesis that a diet with increased intake of yogurt beneficially affects aspects of
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the adiposity or metabolism. The positive effects on blood pressure with consumption of
full fat yogurt suggest a possible relationship to effects on the vasculature should be
further explored.
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Effect of Dairy Consumption on Adiposity and Metabolic Outcomes in Women
According to the Center for Disease Control (CDC) over 40% of adult US women
(>20 years old) were obese in 2013-2014 (Center for Disease Control, 2016). Obesity, or
adiposity, and specifically increased central adiposity, play a critical role in morbidity
and mortality associated with diabetes, metabolic syndromes, and cardio/cerebral
vascular disease in adults (Kaur, Sharma, & Singh, 2015; Kazuhiro et al., 2014;
Mantatzis et al., 2014; Park et al., 2013). In 2011, a taskforce for the National Institutes
of Health (NIH) created the Strategic Plan for NIH Obesity Research “serve as a guide to
accelerate a broad spectrum of research toward developing new and more effective
approaches to address the tremendous burden of obesity” (National Institutes of Health,
2011, p. 7). One way the plan broadly proposed to do this was to “design and test
interventions to promote healthy weight” (National Institutes of Health, 2011, p. 15). In
addition, one objective of this plan emphasizes the importance of investigating factors
related to excess weight gain during “critical periods and life events” (National Institutes
of Health, 2011, p. 21). The taskforce indicated identifying factors unique to a specific
point in the lifespan that could provide important insights for intervention development.
Adolescence, young adulthood, pregnancy, perimenopause, and post menopause are
potential critical periods that have been understudied.
In 2010, approximately 118 million US women were over 20 years of age and
potentially faced the challenges associated with increased adiposity or obesity
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(Census.gov, 2010). Symptoms such as increased abdominal adiposity and decreased
ability to maintain a healthy weight during specific critical life events such as
perimenopause have received much less research attention (Davis et al., 2012; Dasgupta
et al., 2012; Jull et al., 2014; Pimenta, Maroco, Ramos, & Leal, 2014; Sutton et al.,
2010). Additional investigation of such critical time periods and their influence on
adiposity are needed. Furthermore, interventional research to address the increasing
adiposity at all ages is also warranted.
Review of the Literature
The retrieved body of evidence suggests an inverse relationship between dairy
consumption and reduced measures of adiposity in adults (Bhurosy & Jeewon, 2013;
Faghih, Abadi, Hedayati, & Kimiager, 2011, Jones et al., 2013; Josse, Atkinson,
Tarnopolsky, & Phillips, 2011; Holmberg & Thelin, 2013; Murphy et al., 2013; Satija et
al., 2013; Wang et al., 2014; Zemel et al., 2005). Current literature also suggests full-fat
dairy may be more effective for decreasing adiposity in adults than non- or low-fat
products. In the Observation of Cardiovascular Risk Factors in Luxembourg survey, data
were analyzed from 1352 men and women and researchers found those consuming the
highest amounts of whole-fat dairy intakes (milk, cheese, yogurt) had significantly lower
odds of being obese (Crichton & Alkerwi, 2014). Also in another study, Danish women
who consumed less butter and full fat dairy products in their diet were found to be more
likely to have increased waist circumferences (Halkjaer, Tjonneland, Overvad, &
Sorenson, 2009). Outcomes of studies on the effects of dairy products have varied from
overall weight, BMI (Bhurosy & Jeewon, 2013; Martinez et al., 2014), and body
composition (Crichton & Alkerwi, 2014; Faghih et al., 2011, Halkjaer et al., 2009;
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Holmberg & Thelin, 2013; Jones et al., 2013; Murphy et al., 2013; Satija et al., 2013;
Wang et al., 2014).
Unfortunately, most research related to dairy and obesity measures has been
prospective or observational, with very few interventional studies. Even less of these
studies have focused solely on women. Of the few studies found utilizing experimental
designs, several demonstrated significant findings when using dairy as an intervention for
reducing adiposity and improving metabolic measures. Josse et al. (2011) found
increased consumption of dairy foods in premenopausal obese women helped promote fat
mass loss for those on a diet and exercise weight loss program. Also, men and women
who consume yogurt during energy restriction lost 81% more trunk fat than those on the
control diet (Zemel, 2005). Faghih et al. (2011) found significant decreases in waist
circumference in as little as eight weeks in obese women who consumed high doses of
dairy in their experimental study.
Research has also identified a beneficial role of dairy on metabolic markers and
blood pressure (Josse et al., 2011; Nestel et al., 2013; Van Meijl & Mensink, 2013).
Wang et al. (2013) found yogurt consumption was associated with lower levels of
circulating triglycerides, glucose, and lower systolic blood pressure and insulin resistance
in American adults participating in the Framingham Heart Study Offspring (1998-2001)
and Third Generation cohorts (2002-2005).
Few studies have specifically utilized yogurt as a dietary intervention, however,
this specific dietary choice may reduce the risk of becoming obese in adult populations
(Austep, 2014; Martinez et al., 2014; Murphy et al., 2013; Wang, Livingston, Fox, Meigs,
& Jacques, 2013; Zemel et al., 2005.) Martinez et al. (2014) focused on yogurt and found
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consumption was inversely associated with the incidence of obesity in a group of 8,516
Mediterranean men and women. In a seminal study that utilized yogurt as an intervention
for adiposity, Zemel et al. (2005) found obese male and female adults ages 18-50, who
consumed an intervention of yogurt yielded significant results for waist circumference
reduction (Zemel et al., 2005). The Zemel study provided a new avenue for researchers
hoping to find an effective intervention for the obesity epidemic. The role of yogurt
consumption on adiposity and other pertinent metabolic markers in women has not been
well studied and is still unknown. The following study sought to address these gaps in the
science.
Theoretical Framework
The Integrated Theory of Health Behavior Change (ITHBC, Figure 1) was
developed to “increase a person's ability to engage in behavior change to increase his/her
self-management behavior” (Ryan, 2009). Subjects who engage in these selfmanagement behaviors are expected to achieve the initial (proximal) short term outcome
which in turn leads to the longer (distal) outcome of an overall improved health status.
Individualized interventions are used to increase knowledge and beliefs, facilitate social
support, and improve self-regulation skills and abilities. Ryan (2009) advocated that
using a theoretical framework would help advance practice nurses’ focus on assessments,
utilized evidence based interventions, and improve patient outcomes. Using the ITHBC is
expected to help improve interdisciplinary communication and foster holistic
comprehensive care (Ryan, 2009). No known dietary studies utilizing dairy in women
have previously applied the ITHBC as the theoretical framework guiding their research.
Ryan (2009) proposes that knowledge and beliefs and social facilitations in the
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ITHBC contribute to a person’s self-regulation skill and ability, which in turn lead to
achievement of the health outcomes. The ITHBC was used to guide a yogurt intervention
in women (Figure 2).

Figure 2. Integrated Theory of Health Behavior Change for a Yogurt Intervention
(Adapted from Ryan, 2009)
Knowledge and beliefs includes condition specific and personal perception
factors. For use in women, this included women’s knowledge about dairy consumption as
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well their perception that dairy could help them lose weight, decrease abdominal fat, and
improve their metabolic health (such as BP and cholesterol levels.)
Social facilitation for this study was support from other women, family, and/or
friends. Other social facilitation came from healthcare providers who taught the
participant about the yogurt intervention. Access to yogurt (availability, ease of purchase,
financial burden) also were components of the ITHBC’s social facilitation category.
Self-regulation and ability in the ITHBC framework are further broken down into
goals, monitoring, decision making, planning, and evaluation/emotional response. For
this study, goals were related to decrease measures of adiposity (such as waist
circumference/BMI) and improving metabolic outcomes (such as increase HDL levels).
Choosing what brand, flavor, and time of day to consume the yogurt was part of the
decision making category of self-regulation. Planning the consumption of yogurt was
influenced by work, home life, vacations, and typical eating schedules. Although
typically an inexpensive food, cost of yogurt also played a role in planning and grocery
budgeting. Evaluation and emotional response were completed at the end of the study
when the participants reflected on whether they like the yogurt, if they were able to eat it
twice daily, if they felt they could continue eating it routinely after the study, and if they
felt it was helping them lose weight and improve their health.
The outcomes from the yogurt intervention were measured by engagement in selfmanagement behaviors during the study. The proximal outcome was that women would
consume 12 ounces of yogurt daily. This in turn was expected to lead to the distal
outcome of improvement in health status by reducing measures of adiposity and
improving metabolic outcomes through serum laboratory results.
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Conceptual and Operational Definitions
Several variables were utilized to help measure the research hypotheses/question
for this study. The following table (Table 2) outlines the conceptual and operational
definitions of the utilized variables in this study.
Table 2. Conceptual and Operational Definitions
Variable
Non-Fat
Yogurt

Full-Fat
Yogurt

Body Mass
Index (BMI)

Waist
Circumference

Conceptual Definition
A food produced by bacterial (“yogurt
cultures”) fermentation of milk.
Fermentation of lactose creates lactic
acid, which acts on milk protein to give
yogurt its texture and its taste. The fat
content of milk is the proportion of
milk, by weight. Non-fat yogurt has
had the butterfat removed. According to
the USDA regulations skim milk or
“nonfat" milk, can be labeled “fat free”
if it contains less than ½ gram of fat per
serving.
A food produced by bacterial (“yogurt
cultures”) fermentation of milk.
Fermentation of lactose creates lactic
acid, which acts on milk protein to give
yogurt its texture and its taste. The fat
content of milk is the proportion of
milk by weight. Typically in the United
States, “whole milk,” or full fat
products contains at least 3.25%
butterfat.
The body mass index (BMI) is a
measure of relative weight based on an
individual's mass and height.

Numerical measurement of waist often
measured in cm using an
anthropometric (soft flexible) tape
measure. A high waist circumference is
associated with an increased risk for
type 2 diabetes, dyslipidemia,
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Operational
Any brand/flavor/texture of
yogurt made from dairy
cow’s milk which
contained 0 grams of total
fat were to be used in this
study.

Any brand/flavor/texture of
yogurt made from dairy
cow’s milk which contains
at least 6 grams of total fat
were to be used in this
study.

BMI was calculated by
dividing the subject’s
weight in pounds (lbs.) by
height in inches (in)
squared and multiplying by
a conversion factor of 703
(to convert from metric to
standard measurement.
Anthropometric tape was
used to measure half way
between the inferior
margin of the last rib and
the crest of the ilium in the
mid-axillary plane.

hypertension, and cardiovascular
disease. Waist circumference can
provide an estimate of abdominal fat.

Hip
Circumference

Fat Mass %:

Blood Pressure

Insulin

Glucose

Cortisol

Centimeters were utilized.
Detailed procedure steps
described in NHANES
Anthropometric Procedure
Manual (CDC, 20011).
Hip circumference is a measurement of Anthropometric tape was
a person’s hip size in centimeters (cm)
used to measure the
using anthropometric tape. Hip
circumference of the hips
circumference is a measurement of
at the widest part of the
obesity. People with "apple-shaped"
buttocks. Centimeters were
bodies (with more weight around the
utilized. Detailed
waist) face more health risks than those procedure steps described
with "pear-shaped" bodies who carry
in NHANES
more weight around the hips.
Anthropometric Procedure
Manual (CDC, 20011).
The percentage of a person’s body that Number in percent (%)
is not composed of fluids, muscle,
calculated via biobone, and vital organs.
impedance weight scale.
The pressure exerted by circulating
Same as conceptual
blood upon the walls of blood vessels.
definition. Specific
"Blood pressure" usually refers to the
procedure described in
arterial pressure of the systemic
NHANES BP Procedure
circulation, and is often measured in the Manual (CDC, 2009).
upper arm. Blood pressure is expressed
in terms of the systolic pressure over
diastolic pressure and is measured in
millimeters of mercury (mm Hg).
Normal resting blood pressure for an
adult is approximately 120/80 mm Hg.
A peptide hormone produced by beta
Level of (8+ hour) fasting
cells in the pancreas. It regulates the
insulin obtained from
metabolism of carbohydrates and fats.
serum blood draw.
It promotes the absorption of glucose
from the blood to skeletal muscles and
fat tissue.
A monosaccharide found in plants that Level of (8+ hour) fasting
is absorbed directly into the
glucose obtained from
bloodstream during digestion and aids
serum blood draw.
in cellular function.
A glucocorticoid steroid hormone,
Level of (8+ hour) fasting
produced in adrenal glands. It is
cortisol will be obtained
released in response to stress and low
from free cortisol levels
blood glucose levels. Cortisol increases drawn from serum blood.
blood sugar, suppresses the immune
system, and helps with metabolism of
fat, protein, and carbohydrate.
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Total
Cholesterol

Low Density
Lipoprotein
(LDL )
Cholesterol

High Density
Lipoprotein
(HDL)
Cholesterol

Triglycerides

A lipid molecule that is biosynthesized
by all cells since it is a component of
cell membranes. Cholesterol is also a
precursor for the biosynthesis of steroid
hormones, bile acids, and vitamin D.
All foods containing animal fat contain
cholesterol.
LDL is one of the five major groups of
lipoproteins whose particles pose a risk
for cardiovascular disease when they
invade the endothelium and become
oxidized. Lipoproteins are complex
particles composed of multiple proteins
which transport all lipids. They are
typically composed of 80-100
proteins/particles. LDL particles are
often called “bad cholesterol” because
they can transport their content of fat
molecules into artery walls, attract
macrophages, and high levels are
associated and an increased risk of
atherosclerosis.
HDL is one of the five major groups of
lipoproteins. Lipoproteins are complex
particles composed of multiple proteins
which transport all lipids. They are
typically composed of 80-100
proteins/particles. Unlike the larger
lipoprotein particles which deliver fat
molecules to cells, HDL particles
remove cholesterol molecules from the
blood decreasing their risk of
atherosclerosis.
Triglycerides are esters created from
glycerol and fatty acids that act as a
blood lipid to aid in transfer adipose fat
and blood glucose from the liver.

Level of (8+ hour) fasting
total cholesterol obtained
from serum blood draw.

Level of (8+ hour) fasting
LDL cholesterol obtained
from serum blood draw.

Level of (8+ hour) fasting
HDL cholesterol obtained
from serum blood draw.

Level of (8+ hour) fasting
Triglycerides obtained
from serum blood draw.

Research Hypotheses and Question

The objective of this study was to improve the nutritional and metabolic health of
women. Specific research hypotheses (Ha) and the research question (RQ) were as
follows:
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Ha1: Yogurt consumption will have a beneficial effect on metabolic outcomes of
women.
Ha1a: This effect will be greater in those consuming full fat products.
Ha2: Yogurt consumption will have a beneficial effect on measures of adiposity
in women.
H2a: This effect will be greater in those consuming full fat products.
RQ1: Will yogurt consumption be a feasible dietary intervention for improving
metabolic and adiposity outcomes in women?
Research Design
Guided by the ITHBC (Ryan, 2009), an experimental design was utilized to
address the study objectives. The concepts from the ITHBC were used as a basis to
develop an intervention related to the prevention or reduction of adiposity and
improvement of metabolic outcomes in women. The study participants were randomly
assigned to one of two intervention groups or a control group. The two interventional
groups received yogurt (i.e., the independent variable) while the control group was asked
to consume their typical diet during the study, making no alterations to foods typically
consumed. After 12 weeks, all groups were measured on the same measures of adiposity
and metabolic markers (i.e., the dependent variables).
Methods
Sample. The accessible population for this study was adult women living in north
Texas. Recruitment was performed at a large obstetrics and gynecology practice as well
as several other community locations in north Texas. Inclusion criteria included: (a)
women who were at least 18 years old and (b) those who were able to read, speak, and
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write English. Exclusion criteria included women with: (a) a diagnosis or currently taking
medication for diabetes or hyperlipidemia, (b) lactose intolerance, (c) allergy to dairy
products, (d) those who have had a greater than 20-pound weight change in the past year
and/or (e) those who were pregnant or were within six weeks after delivery.
Informed Consent/Human Subjects Protection. Protection of the rights of the
participants in this project was upheld through a variety of measures implemented to
ensure safety, privacy, and confidentiality for all of those involved. All procedures were
evaluated and approved by the IRB at the University of Texas at Tyler. Prior to signing
the informed consent, full disclosure of the study’s general purpose, benefits, risks,
participants’ rights, and responsibilities were discussed with all participants. Regulations
for the Health Insurance Portability and Accountability Act (HIPAA) for protected health
information was maintained at all times and HIPAA consents were obtained.
Measures/Instruments. Survey instruments. A researcher-developed Participant
Demographic Survey was used to collect pertinent patient demographic data. Participants
provided dietary data about their use of yogurt by completing an 8-item Dairy
Consumption Questionnaire, Daily Yogurt and Dairy Form, and a Daily Dairy Form). A
6-item Post Study Feasibility Survey was also used. After development, the researcher
sent each of these instruments to content experts, colleagues, and others not familiar with
the research to elicit feedback on the wording and face validity. The forms were
reorganized and reworded based on feedback.
Metabolic/Physiologic Outcomes. Ha1 was tested by measuring the effect of the
yogurt on: blood pressure, fasting serum glucose, insulin, lipid panel (total cholesterol,
low density lipoprotein [LDL], high density lipoprotein [HDL], and triglycerides), and
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free cortisol levels. Labs were collected at the contracted laboratory and were prepared,
stored, and transported according to specific local lab protocols. To reduce bias, a single
laboratory was utilized for all blood analyses; measurement of blood pressure was
obtained using the equipment and instruction standards described in the National Health
and Nutritional Examination Survey (NHANES) Blood Pressure Procedures Manuals
(Centers for Disease Control, 2009).
Adiposity outcomes. Ha2 was tested by measuring the effect of the yogurt
intervention on: body mass index (BMI), waist circumference (cm), hip circumference
(cm), and body fat percent. Collection of weight and height (to calculate BMI), as well as
waist and hip circumferences was obtained using the equipment and instruction standards
described in the National Health and Nutritional Examination Survey (NHANES)
Anthropometry Manuals (Centers for Disease Control, 2011). The longstanding reputable
history of NHANES made their manuals an appropriate choice for this study.
In a recent study of women, Direk and colleagues (2013) found that
anthropometric measures predicted abdominal fat almost equally as well as Computed
Tomography (CT) or Dual Energy X-ray Absorptiometry (DXA) scanning. Although CT
and DXA are considered the gold standard for body fat percent measurement in clinical
settings, due to funding limitations and access, these tools were not utilized for this study.
Direk and colleagues’ study (2013) lends support to the use of anthropometric measures
as estimates of visceral fat. Furthermore, a professional grade bio-impedance scale was
used to determine body fat composition to assess percentage of body fat. Bio-impedance
uses electrodes similar to an electrocardiogram (EKG) to run an imperceptible electrical
current through the body. Lean tissue is a good conductor of electricity while fat tissue is
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not. The resistance of the flow of the electrical current is measured by an analyzer to
calculate the body composition. Electrical bio-impendence monitoring has been utilized
in a number of published studies as an alternative means to CT/DXA to assess total body
fat percent.
Compliance and feasibility. The Daily Yogurt and Dairy Form was used to
provide an answer to RQ1. This format enabled participants to exercise control over some
of the diet decisions they made as well as promote behaviors of self-regulation, an
integral concept in the ITHBC model. This form was utilized by participants to track the
number of ounces, fat (grams), and brand/flavor of yogurt consumed each day. In
addition, the Post Study Feasibility Survey was administered to assess participants’
likelihood to continue the use of yogurt as part of their nutritional intake after the study
was completed.
Intervention description. The non-fat intervention group (NF) was asked to
consume 12 total ounces of non-fat yogurt per day for 12 weeks. Participants were
allowed to purchase any brand, flavor, or texture of yogurt of their choice. Participant
were instructed to consume commercial dairy milk yogurt (from cows) that did not
exceed 160 calories, 18 grams of carbs, or 0 grams of fat (per 6 ounce serving). They
could consume the yogurt at any time each day in combination with another meal, as a
meal replacement, or as a snack. They were instructed to record the amount in ounces and
brand/flavor of yogurt consumed each day. The participants were asked to consume all
other dairy products in the same amounts and frequencies as before the study keeping
their habitual diet. They were also asked to record both the yogurt and dairy consumption
for each day on the Daily Yogurt and Dairy Form.
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The full-fat intervention group (FF) was asked to consume 12 ounces of full fat
yogurt per day for 12 weeks. There was no upper limitation on calories, carbs, or fat.
Participants were instructed to consume yogurt with at least 6 grams of fat per 6 ounce
serving. They were also asked to record the amount in ounces, grams of fat, and
brand/flavor of yogurt consumed each day. The participants were asked to consume all
other dairy products in the same amounts and frequencies as before the study to maintain
their habitual diet. They were asked to record both the yogurt and dairy consumption for
each day on the Daily Yogurt and Dairy Form.
The control group (CG) was asked to make no changes to their current dietary
habits. They were instructed to document dairy consumption on the Daily Dairy Form.
Though this could have heightened the awareness of consuming dairy products, with the
emphasis not on yogurt it was expected that they would not consume more yogurt than
usual. The form also served as a means to assess typical yogurt intake within the sample.
Data Collection. Participants were recruited through locally posted community
flyers and letters to current patients at a large obstetrics and gynecology practice. All
participants were interviewed in person, via phone, or email (depending on how they
contacted the PI) to assess for study eligibility. The researcher’s contact information was
listed for all flyers posted in the community. Staff at the obstetrics and gynecology
practice was instructed on how to inform prospective participants of the study and next
steps for contacting the researcher when interested women were identified.
If inclusion criteria were met, potential participants were asked to meet with the
PI in an initial session in which the purpose and procedures of the study were disclosed.
After signing the IRB-approved consent and HIPAA forms, participants were randomly
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assigned to one of three groups (a control group, a non-fat yogurt group, or a full-fat
yogurt group) by drawing a sealed envelope.
After randomization, baseline demographic surveys, anthropometric
measurements, and lab work were then obtained by the PI and entered into each of the
participant’s individual file. All data collection was performed in a private room to ensure
privacy. Following baseline data collection, participants were instructed not to make any
major diet changes during the course of the 12-week study unless instructed to do so as
indicated by the group assignment. They were also asked not to change their activities or
exercise regimens during this time. Participants were instructed to report any new
medications, changes in medications, or changes in health status. Participants in the fullfat and non-fat yogurt groups were given a Daily Yogurt and Dairy Form to specifically
document the amount and type of yogurt consumed each day, as well as other dairy
products consumed. Participants in the control group completed the Daily Dairy Form to
document all dairy intake on a daily basis. The PI advised participants to submit forms
weekly to encourage and assess compliance with the intervention. Electronic submission
via email was recommended but postage paid options for regular mail were also
available. Subjects were then sent to the contracted lab to have their blood drawn after the
initial body assessments. At the end of the 12-weeks, anthropometric measurements and
lab work were reassessed. In addition, the Post Study Feasibility Survey was distributed
to group participants to obtain feedback on the intervention study. All survey data and
assessment findings were completed on paper and were stored in a locked file in a locked
office accessible only to the PI.
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Procedure. All study data were transcribed into a password protected Statistical
Program for the Social Sciences (SPSS version 20.0) database for analysis. Data was
assessed for accuracy, outliers, and missing responses prior to conducting analysis.
Discrete variables were examined for accuracy. Continuous variable means and standard
deviations were examined for errors and to assess for outliers. Descriptive statistics were
calculated for each variable. For continuous variables, range, mean, median, and standard
deviation were used. For categorical variables, mean, frequency, and contingency tables
were used. Chi-square tests (for nominal level data) and ANOVA (for continuous level
data) were used to compare the distribution of the demographics of the three groups at
baseline. Post hoc analyses were conducted to determine the differences.
Feasibility (RQ1) was assessed via time required for recruitment, attrition rate,
Daily Yogurt/Dairy Consumption Form completion, and responses to the Post Study
Feasibility Survey.
Results
Participant Characteristics. A total of 59 healthy adult women aged 18 to 69
(mean 34.1 SD 12.48) were initially enrolled in this study and 47 completed the research
study. Table 1 shows the full fat (18), non-fat (14), and control subjects (15) were similar
overall based on demographics. The participants in the study were primarily white
(72.9%), had some college education (81.4%) and had some current form of health
insurance (79.9%). Baseline participant characteristics are summarized in Table 3. No
significant differences were found for any demographic variable across the groups.
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Table 3. Baseline Demographics of Subjects
Variable
Age
18-30
31-43
43-56
57+
Marital Status
Married
Divorced
Never Married
Race
White
Black
Asian
Other
Education
8th grade
High School
Some College
College Grad
Post Grad
Working Status
No
Yes 40+ hrs.
Yes 30-40 hrs.
Yes 20-30 hrs.
Yes less 20 hrs.
Insurance Status
Employer
Self-Insured
Medicaid
Medicare
No Insurance
Other
Exercise
Minutes per
Week

Full-Fat (n=18)

Non-Fat (n=14)

Control (n=15)

10 (55.6)
4 (22.2)
4 (22.2)
0

6 (42.9)
5 (35.7)
3 (21.4)
0

7 (46.7)
5 (33.3)
1 (6.7)
2 (13%)

8 (44.4)
3 (16.7)
7 (38.9)

7 (50.0)
3 (21.4)
4 (28.6)

9 (60.0)
0 (0)
6 (40.0)

13 (72.2)
2 (11.1)
1 (5.6)
2 (11.1)

8 (57.1)
1 (7.1)
1 (7.1)
4 (28.6)

12 (80.0)
3 (20.0)
0 (0)
0 (0)

2 (11.1)
3 (16.7)
6 (33.3)
7 (38.9)
0 (0)

0 (0)
4 (28.6)
4 (28.6)
5 (35.7)
1 (7.1)

1 (6.7)
1 (6.7)
3 (20.0)
8 (53.3)
2 (13.3)

11 (61.1)
2 (11.1)
2 (11.1)
2 (11.1)
1 (5.6)

9 (64.3)
2 (14.3)
1 (7.1)
2 (14.3)
0 (0)

9 (60.0)
3 (20.0)
3 (20.0)
0 (0)
0 (0)

11 (61.1)
3 (16.7)
0 (0)
0 (0)
2 (11.1)
2 (11.1)

10 (71.4)
1 (7.1)
2 (14.3)
0 (0)
0 (0)
1 (7.1)

9 (60.0)
1 (6.7)
0 (0)
1 (6.7)
4 (26.7)
0 (0)

125.27 ± 25.48

101.78 ± 33.5

145.33 ± 30.45

P
Value1
.368

.453

.300

.535

.822

.753

.607

1

P values were created using the x2 statistic for ordinal level data and mean with SE for continuous variables.

Metabolic Indicators (Ha1). Baseline blood values were compared across all
groups for Lipid Panel (Total Cholesterol, LDL, HDL, Triglycerides), Glucose, Insulin,
and Cortisol, and indicated no difference in these values at baseline (Table 4). For each
of these measures, a change score was computed to determine the change for each
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participant from baseline to the final measurement. One-way ANOVA was used to
compare change scores for each measure across groups. Differences in change scores
were not statistically significant when comparing groups according to change in: Total
Cholesterol, F (2,42) = .289, p = .753, LDL Cholesterol, F (2,42) = .287, p = .752, HDL
Cholesterol, F (2,42) = .621, p = .543, Triglycerides, F (2,42) = .377, p= .688, Cortisol, F
(2,41) = .635, p = .535|, Insulin, F (2,42) = .615, p = .546|; or Glucose, F (2,42) = .706, p
= .500.
Table 4. Baseline Laboratory Values

1

Variable

Full-Fat (n=18)

Non-Fat (n=14)

Control (n=15)

Serum Lipid Panel
Total Cholesterol
LDL Cholesterol
HDL Cholesterol
Triglycerides
Serum Glucose
Serum Insulin
Serum Cortisol

171.69 ± 4.82
96.05 ± 5.10
54.70 ± 3.35
101.76 ± 10.45
87.76 ± 1.86
12.17 ± 2.77
12.47 ± 1.32

157.92 ± 8.24
84.78 ± 6.92
53.48 ± 2.91
98.14 ± 17.83
85.92 ± 1.75
9.78 ± 2.71
11.00 ± 1.657

181.72 ± 11.37
105.09 ± 10.48
59.36 ± 3.45
87.09 ± 28.93
87.81 ± 3.89
8.63 ± 2.54
10.81 ± 1.33

Values are means ± SE

Anthropometric Measures (Ha2). Baseline and post intervention anthropometric
measures were compared across all groups for weight, BMI, body fat percent (%), waist
circumference, hip circumference, and blood pressure. For each of these measures, a
change score was computed to determine the change for each participant from baseline to
the final measurement. One-way ANOVA was used to compare change scores for each
measure across groups. Differences in change scores were not statistically significant
when comparing groups according to change in: Weight F, (2, 46) =.918, p=.407, BMI, F
(2, 46) = .263, Body Fat Percent, F (2, 46) = .977, p=.385, p=770; and Hip
Circumference, F (2, 46) =.711, p=.497. Waist Circumference showed a significant
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change, F (2, 46) =14.17, p<.001, over 12 weeks in all three groups but did not differ
statistically between groups (Table 5). There were statistically significant differences
when comparing groups according to change in systolic blood pressure, F (2, 46) =
10.06, p < .001, and diastolic blood pressure, F (2, 46) = 6.85, p = .003. The full fat group
showed a significantly greater reduction in overall blood pressure over the 12 weeks
when compared to the non-fat and control groups.
Table 5. Anthropometric Means at Baseline and at 12 weeks.
Variable
(N=47)

Weight
BMI
Waist
Circumference
Hip
Circumference
Body Fat %
Systolic BP
Diastolic BP

Full Fat

Baseline
200.84 ±
61.42
34.25 ±
9.21
99.02 ±
19.66
118.25 ±
14.41
41.83 ±
9.05
122.60 ±
12.08
78.70 ±
8.82

Non Fat

12 weeks
202.34 ±
64.80
34.32 ±
9.77
94.77 ±
19.32
118.00 ±
14.69
41.92 ±
8.72
117.11 ±
7.84
74.67±
7.19

Baseline
190.73 ±
44.78
32.77 ±
9.21
94.97 ±
13.25
116.72±
14.84
40.6 ±
8.68
120.90 ±
11.47
77.27 ±
7.07

Control

12 weeks
179.07 ±
40.00
31.4 ±
7.08
89.71 ±
12.64
111.28 ±
12.46
38.67 ±
8.47
127.35 ±
10.66
79.64 ±
7.12

Baseline
176.15 ±
53.62
29.18 ±
9.21
88.29 ±
15.62
111.64 ±
15.08
37.04±
10.61
118.17±
12.43
77.35 ±
9.02

P
Value
12 weeks
177.57 ±
55.67
29.67 ±
8.87
86.20 ±
15.14
110.53 ±
14.87
36.32 ±
11.52
126.73 ±
14.09
80.33 ±
10.89

.407
.385
.231
.497
.385
.000*
.003*

*Denotes Statistically Significant Value

Feasibility. The recruitment of new participants took close to eight months from
the initial start date. Fifty-nine participants completed all initial surveys, consents and
initial anthropometric body assessments. However, of the 59 participants, 12 never went
to the laboratory to have the serum blood markers completed at baseline, thus having
incomplete files. Of the 12 who did not have the blood work done at baseline, two of
these subjects did continue the study without the lab work portions completed. The other
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10 did not finish the study. Forty-seven participants (80%) completed the 12-week study
with all baseline and post intervention assessments completed.
Participants in the yogurt groups were instructed to consume 12 ounces of yogurt
per day (equating to a projected 1008 ounces during the entire 12 weeks if they consumed
all servings). The actual average yogurt consumption was 665.62 (SD= 268.47) ounces
for full fat group participants, 652.25 (SD= 258.48) for non-fat group participants and
23.24 (SD= 26.35) ounces for the documentation group (who were instructed to keep
their habitual diet). Most participants in the intervention groups indicated they missed
more than 10 servings of yogurt during the study according to the Post Study Feasibility
Survey.
In addition to ordinal level questioning, the Post Study Feasibility Survey
contained a response set that offered participants a narrative section to document
comments or concerns with the yogurt intervention or other aspects of the research study.
Very few comments were documented by the participants on this portion of the survey.
However, it should be noted that several participants from the full fat group did voice
some difficulty in finding full fat yogurt which contained at least 6 grams of fat. Many
subjects reported that when searching for products utilizing terms such as “traditional,”
“whole milk,” or simply looking for products that lacked the terms non-fat or low-fat,
was a challenge. Some stated that even products not claiming to be low fat often times
had less than 6 grams of fat per serving. Others participants in this group reported they
could only find full fat whole milk products at health food or organic type stores and that
their typical grocery store’s selection of full fat yogurts was quite limited.
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Discussion
Results from this study indicate no statistically significant differences incurred in
subjects from consuming yogurt as a dietary intervention for measures of adiposity or
body composition. Since yogurt compliance to the full 12 ounces per day procedure was
a challenge for many participants, it is possible that a protocol requiring less ounces per
day (only 1 serving instead of two) over a longer period of time may offer better
compliance. Interestingly there were also no significant differences in participants who
consumed full fat verses nonfat products on the outcome measures. Fat sources have
historically been marketed as detrimental, particularly to those with cardiovascular
disease and diabetes. However, no statistically significant correlation was seen in the
biomarkers or body measurements of those consuming full fat, versus non-fat yogurt,
versus typical diet, over the 12-week intervention. Further investigation of the role of
dietary intake of fat on common metabolic indicators of cardiovascular disease and
diabetes is warranted.
A modest decrease in systolic and diastolic blood pressures of full fat group
participants was seen. In animal and in vitro studies it has been suggested that bioactive
substances found in dairy have been shown to have an inhibitory effect on angiotensin
converting enzyme but further research in human participants is needed (Munn, Sibley,
Brundage, Ismail, & Earthman, 2013). In a study of 89 adults with hypertension, DrouinChartier et al., (2014) found dairy consumption to have a positive blood pressure
lowering effect in men with mild to moderate hypertension but found that it may have a
worsening effect in women. In a study aimed to examine the longitudinal association of
dairy consumption with the changes in blood pressure (BP) and the risk of incident
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hypertension (HTN) among adults, Wang, Fox, Troy, Mckeown, and Jacques (2015)
utilized 2,636 Framingham Heart Study Offspring Cohort members (1991–2008) to
investigate such relationships. They found total dairy and total low-fat/fat-free dairy
intakes were inversely related to changes in diastolic blood pressure. Also, they found
that each additional serving of yogurt consumed was associated with a 6% (95 % CI 1,
10) reduced risk of incident hypertension. While there has been support for changes in
blood pressure associated with yogurt or dairy consumption, there remains a need for
relevant research to establish a body of evidence further investigating these relationships.
In terms of feasibility, most participants indicated they would continue to
consume yogurt after the study but few felt they would eat it daily. In terms of
sustainability the question of convenience in purchasing full fat products needs further
scrutiny. Marketing strategies are aimed at low-fat or non-fat products and make up a
bulk of the products on stores shelves. Further investigations of the differences in full fat
dairy products and the health benefits or concerns of such must come to light if there will
be any paradigm shift in the marketing and economics of our food industry. At a
minimum, if there is no distinguishable difference in the health benefits or harms of full
fat yogurt compared to non-fat, which would most persons prefer to consume? Artificial
sweeteners are often utilized in non-fat products to help replace some of the taste lost to
the reduction of savory fat content. Emerging evidence demonstrating the impact of
artificial sweeteners on obesity may support the marketability of full-fat yogurt.
Strengths, Limitations, and Difficulties
Strengths. The major strength of this study was its experimental design. Many of
the studies reviewed in the literature were prospective or cross sectional. Very few
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randomized controlled studies utilizing yogurt have been completed. To our knowledge,
no experimental studies utilizing yogurt in only women had been done. Utilizing multiple
measures of adiposity as well as several biomarkers were also strengths in this study.
Additionally, yogurt is typically inexpensive, and is a widely available dietary
intervention at most local grocery stores which contributes to sustainability.
Limitations. As with any longitudinal study, attrition was a limitation.
Oversampling was done to allow for loss of participants. Utilizing only a few local
community sites for assessment completion was a limitation for a few participants who
said they had to drive over 20 minutes to get to the clinic. Woman in the intervention
groups reported they become tired of consuming 12 ounces of yogurt every day. Very
few participants were still eating 12 ounces of yogurt towards the end of 12 weeks. There
were no restrictions made for the brand, flavor, texture or time of day to eat the yogurt,
but most women stated they were “just tired of eating it every day.”
The potential for confounding variables, despite exclusion criteria, could not be
entirely controlled. Since standardization of only a few (not all) nutritional parameters
was performed, other nutritional co-variables still exist (such as caloric intake).
Furthermore, actual exercise or energy expenditure was not measured or controlled.
Participants self-reported exercise (in minutes) at the initial and final assessments with no
significant differences between groups. Participants were asked not to make any other
changes in exercise or diet during the study. Although this opened up the possibility of
confounding variables, it also reflected a real-world approach and helped determine if
yogurt consumption was feasible without placing additional demands or restrictions on
participants. Maintaining their previous behaviors mitigated the source and impact of
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extraneous behaviors since the participants served as their own controls.
Some variability and human error was possible when obtaining anthropometric
measurements. Body composition differences, racial and ethnic differences, and clinician
technique could all have led to discrepancy. Body composition differences and racial and
ethnic differences were collected in baseline data. Variances in clinician technique was
addressed by using the same person, equipment, and lab to collect and analyze data to
help reduce this limitation. The self-reported nature of food consumption was also a
limitation. Participants may have felt inconvenienced to write in a daily log. This may
have led to falsification, inaccurate recall, or under-reporting of consumption.
Challenges. The time it took for recruitment of an adequate number of
participants was a challenge in this study. Participants were offered free assessments of
body composition and several metabolic indicators at two time points but some still did
not seek out these free services. Attrition was also a problem. Two participants reported
they did not want to eat the yogurt after 1-2 weeks and decided to stop the study, but the
rest who did not finish were lost to inability to follow up. It should be noted that a
majority of those who did not follow up were unreachable within the first 2 weeks of the
study indicating they likely never began the intervention despite enrolling in the study.
Financially, some women found it to be a burden to purchase full fat yogurt which some
felt was more difficult to find and often was located at health food or natural/organic type
stores instead of their typical grocery store which made it more costly. The major
difficulty in conducting this type of research was the fiscal resources necessary to
conduct the study. Women could not be asked to pay out of pocket to cover blood work;
providers could not be expected to provide services for free. In this study, the PI, who is a
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women’s health nurse practitioner, provided the assessments at no cost. The lab that
supports the PI’s practice negotiated the lowest cost possible to provide lab services and
still cover expenses. Intramural funding assisted in covering these study-related expenses.
Conclusion
Increased adiposity and declining metabolic health in women results in negative
consequences to health. The current literature supports the hypothesis of dairy as an
intervention, but too few interventional studies have been completed. This study helps to
address the gaps in science that are crucial for this population. Although no known prior
use in adiposity studies of women, the ITHBC provided a sound theoretical basis to guide
the research. The National Institutes of Health’s (NIH) Strategic Plan for NIH Obesity
Research called researchers to develop effective interventions to alleviate the burden of
obesity (National Institutes of Health, 2011). Promoting healthy weight during critical
periods and life events is one way NIH proposed to accomplish this. This researcher
accepted the challenge from NIH, and the findings from this study will contribute to the
body of knowledge in hopes of improving the health outcomes for women.
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Chapter 5
Conclusions and Recommendations
The prevalence of obesity was 36.5% among U.S. adults during 2011–2014
(CDC, 2015). Flegal, Kit, Orpana, & Graubard (2013) performed a systematic review of
reported hazard ratios (HRs) of all-cause mortality for overweight and obesity relative to
normal weight in the general population. They found relative to normal weight, obesity
was associated with significantly higher all-cause mortality. Obesity concerns as risk
factors for diabetes and cardiovascular disease have been in the literature for decades.
Additionally, obesity related morbidity and mortality issues are also a financial burden on
our already suffering healthcare dollars. A recent meta-analysis found that the “annual
medical spending attributable to an obese individual was $1,901 ($1,239-$2,582) in 2014
USD, accounting for $149.4 billion at the national level” (Kim & Basu, 2016).
The investigation of concerns of the symptoms of perimenopause is just one
vulnerable group that would benefit from further knowledge of the complex relationships
between diet and measures of metabolism and adiposity. Findings from the brief review
of symptoms of the perimenopause demonstrate that increase abdominal fat does play a
role in the menopause transition, but is poorly understood. Some groups have focused on
nutrition concerns of this population but again without clear guidelines to direct
healthcare providers.
Research stakeholders (NIH Strategic Plan for Obesity, 2011) are actively
encouraging intervention research studies. Funding opportunities are available for all
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levels of researchers.
The general topic of this dissertation was delivering a yogurt intervention for the
expected benefits in the measures of adiposity and metabolism is an emerging research
subject. There is conflicting data in the literature regarding dairy consumption, including
yogurt specifically, as a health intervention. Observational studies are demonstrating
possible relationships but no clear answer has been ascertained. More specifically the
benefits for women, and for women at certain life points, is far from clear. Additionally,
the correlations between the amounts of dairy fat in the products being studied also
provides a covariate for further scrutiny. The findings from this research project
demonstrated no acute effect that consuming yogurt had on measures of adiposity but did
peak further question into the suggestion that certain types of dairy may play a positive
role on blood pressure. This project also creates further questions as to why no significant
differences were seen on serum biomarkers with participants consuming full fat versus
non-fat product, when for decades, fat has been touted as harmful to our metabolic health.
Understanding these relationships may assist a multitude of health related
disciplines as they search for better ways to address problems of health and obesity in the
United States. Nursing, medicine (cardiovascular, endocrine), nutrition, mental health,
advocates are working tirelessly to seek out answers. Other interest groups such as
economists, public health activists, farming/dairy corporations, and financial stakeholders
are also actively involved. The problem of obesity spares no gender, race or ethnicity and
millions would benefit for further investigation of this research project.
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Appendix A: Institutional Review Board Approval

THE UNIVERSITY OF TEXAS AT TYLER
3900 University Blvd. • Tyler, TX 75799 • 903.565.5774 • FAX: 903.565.5858

Office of Research
and Technology
Transfer
Institutional Review
Board

July 28, 2015
Dear Ms. Boyet,
Your request to conduct the study: Effect of a Yogurt Intervention on Adiposity and
Metabolic Outcomes in Perimenopausal, IRB# SUM2015-105, has been approved by The
University of Texas at Tyler Institutional Review Board under expedited review.
This approval includes the written informed consent that is attached to this letter,
and your assurance of participant knowledge of the following prior to study
participation: this is a research study; participation is completely voluntary with no
obligations to continue participating, and with no adverse consequences for nonparticipation; and assurance of confidentiality of their data.
In addition, please ensure that any research assistants are knowledgeable about
research ethics and confidentiality, and any co-investigators have completed human
protection training within the past three years, and have forwarded their
certificates to the IRB office (G. Duke).
Please review the UT Tyler IRB Principal Investigator Responsibilities, and
acknowledge your understanding of these responsibilities and the following
through return of this email to the IRB Chair within one week after receipt of
this approval letter:
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Appendix A: Institutional Review Board Approval Continued








This approval is for one year, as of the date of the approval letter
The Progress Report form must be completed for projects extending
past one year. Your protocol will automatically expire on the one year
anniversary of this letter if a Progress Report is not submitted, per HHS
Regulations prior to that date (45 CFR 46.108(b) and 109(e):
http://www.hhs.gov/ohrp/policy/contrev0107.html
Prompt reporting to the UT Tyler IRB of any proposed changes to this
research activity
Prompt reporting to the UT Tyler IRB and academic department
administration will be done of any unanticipated problems involving
risks to subjects or others
Suspension or termination of approval may be done if there is evidence of
any serious or continuing noncompliance with Federal Regulations or any
aberrations in original proposal.
Any change in proposal procedures must be promptly reported to the IRB
prior to implementing any changes except when necessary to eliminate
apparent immediate hazards to the subject.

Best of luck in your research, and do not hesitate to contact me if you need any
further assistance.
Sincerely,

Gloria Duke, PhD, RN
Chair, UT Tyler IRB
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Appendix C: Recruitment Flyer

The University of Texas at Tyler is looking for participants for a clinical nutrition study
here in north Texas.
Are you a female over 18?
Are you interested in being a part of a clinical research study which focuses on weight
and nutrition?
We invite you to contact us for more information about this study.
Email: eboyet@patriots.uttyler.edu Phone: 940-891-3600
The primary investigator for this research study is Eryn Boyet, RN, MSN, WHNP-BC.
Ms. Boyet is a Women’s Health Nurse Practitioner at Noble Obstetrics & Gynecology.
She is also nursing faculty at North Central Texas College. You may contact her at the
above email address for any questions
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Appendix D: Recruitment Letter

Dear _______________________,
As a loyal patient of Noble Obstetrics & Gynecology we wanted to let you know about an
upcoming research study at our office that you may be interested in participating in. One
of our nurse practitioners, Eryn Boyet, RN, MSN, WHNP-BC, is currently initiating a
research project for perimenopausal women. This study is done in conjunction with Ms.
Boyet’s doctoral research (dissertation) at the University of Texas at Tyler.
The focus of this research study is on nutrition, weight, body fat, and the associated risks
for cardiovascular disease and diabetes. The research study will involve body
composition assessments, blood work, dietary evaluations, and the use of a 12 week long
dietary intervention.
The study focuses on women who are over 18 years old. The research study will be
completely voluntary and you may stop at any time.
If you would like more information about this study or think you may be interested in
participating, please contact the office below so we can see if you qualify to participate.
If you would rather, you may also email the researcher directly for more information at
the email address listed below.
We look forward to hearing from you!
Noble Obstetrics Office Phone: 940-891-3600
Researcher’s Email: eboyet@patriots.uttyler.edu

88

Appendix E: Informed Consent
THE UNIVERSITY OF TEXAS AT TYLER
Informed Consent to Participate in Research
Institutional Review Board #
Approval Date:
1. Project Title: Effect of a Yogurt Intervention on Adiposity and Metabolic Outcomes
in Women
2. Principal Investigator: Eryn Boyet, RN, MSN, WHNP-BC
3. Participant’s Name: ________________________________________
To the Participant:
You are being asked to take part in this study at The University of Texas at Tyler
(UT Tyler). This permission form explains:


Why this research study is being done.



What you will be doing if you take part in the study.



Any risks and benefits you can expect if you take part in this study.

After talking with the person who asks you to take part in the study, you should be able
to:
 Understand what the study is about.


Choose to take part in this study because you understand what will happen

4. Description of Project
The purpose of this study is to determine the effects that eating certain dairy products has
on women’s weight, body fat and certain blood tests. The focus of this study involves
women. Doctors and nurses can use findings from your participation in this study to find
ways to help women manage their weight and reduce their health risks.
5. Research Procedures
If you agree to be in this study, we will ask you to do the following things:
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You will be asked to set up a meeting with the researcher to talk about your diet,
habits, health status, medication usage, and activity level.



You will be asked to record on paper when you eat certain foods during this
study. You will submit these recordings to the researcher on a weekly basis for
three months.



You may be asked to consume specific types of yogurt during this study.



Your height, weight, waist and hip circumference, blood pressure, and body fat
percent will be measured at the beginning and end of this study.



Your blood will be drawn for cholesterol, triglycerides, glucose, insulin, and
cortisol at the beginning and end of this study.

6. Side Effects/Risks
Side effects may occur from changing my diet in this study. Minor discomforts such as
upset stomach, increased gas, or changes in bowel habits may occur from participating in
this research study. By signing this consent I acknowledge that I do not have any known
allergies to any dairy products. However, the possibility of an allergic food reaction could
still occur. If any side effects occur during this study I will notify the researcher right
away. Injury may result from laboratory phlebotomy procedures necessary for blood
collection. Although rare, I acknowledge that tissue injury, hemorrhage, and/or infection
are possible risks. If any injury occurs during this study I will notify the researcher right
away.
7. Potential Benefits
Healthcare providers can help other women by learning about the role of dairy in our
diets.
Understanding of Participants
8. I have been given a chance to ask any questions about this research study. The
researcher has answered my questions.
9. If I sign this consent form I know it means that:


I am taking part in this study because I want to. I chose to take part in this study
after having been told about the study and how it will affect me.



I know that I may choose not be in this study. If I choose to not take part in the
study, then nothing will happen to me as a result of my choice.
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I know that I have been told that if I choose to be in the study, then I can stop at
any time. I know that if I do stop being a part of the study, then nothing will
happen to me.



I will be told about any new information that may affect my wanting to continue
to be part of this study.



The study may be changed or stopped at any time by the researcher or by The
University of Texas at Tyler.



The researcher will get my written permission for any changes that may affect
me.

10. I have been promised that that my name will not be in any reports about this study
unless I give my permission.
11. I also understand that any information collected during this study may be shared as
long as no identifying information such as my name, address, or other contact
information is provided). This information can include health information. Information
may be shared with:


Organization giving money to be able to conduct this study.



Other researchers interested in putting together your information with information
from other studies.



Information shared through presentations or publications.

12. I understand The UT Tyler Institutional Review Board (the group that makes sure
that research is done correctly and that procedures are in place to protect the safety of
research participants) may look at the research documents. These documents may have
information that identifies me on them. This is a part of their monitoring procedure. I also
understand that my personal information will not be shared with anyone.
13. I have been told about any possible risks that can happen with my taking part in this
research project.
14. I also understand that I will not be given money for any patents or discoveries that
may result from my taking part in this research.
15. If I have any questions concerning my participation in this project, I will contact the
principal researcher: (Eryn Boyet) at (940-224-8167) or email
(eboyet@patriots.uttyler.edu).
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16. If I have any questions concerning my rights as a research subject, I will contact Dr.
Gloria Duke, Chair of the IRB, at (903) 566-7023, gduke@uttyler.edu, or the
University’s Office of Sponsored Research:
The University of Texas at Tyler
c/o Office of Sponsored Research
3900 University Blvd
Tyler, TX 75799
I understand that I may contact Dr. Duke with questions about research-related injuries.
17. CONSENT/PERMISSION FOR PARTICIPATION IN THIS RESEARCH STUDY

I have read and understood what has been explained to me. I give my permission to take
part in this study as it is explained to me. I give the study researcher permission to
register me in this study. I have received a signed copy of this consent form.
____________________________ _ ___ _
Signature of Participant

__________
Date

______________

_____________________________________
Witness to Signature
18. I have discussed this project with the participant, using language that is appropriate
and the participant understands. I believe that I have fully informed this participant of the
nature of this study and its possible benefits and risks. I believe the participant
understood this explanation.
_________________________________
Researcher/Principal Investigator

_______________
Date

IRB approved October 2011; rev 03-26-12
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Appendix F: HIPAA Consent

The University of Texas at Tyler
Institutional Review Board
RESEARCH PARTICIPANT AUTHORIZATION TO USE PROTECTED
HEALTH INFORMATION

This form is to be signed by research participants in addition to the written
Informed Consent, or, in the case that a written informed consent is authorized to
be waived and is not used, this form must be signed anytime that protected health
information will be used during a research project.
This does not authorize release of protected health information from any health care
organization or provider.
Your records are confidential but may be revealed to appropriate institutional or
federal authorities.
There is a federal law (HIPAA), which protects the confidentiality of your health
information. This section of the informed consent explains how your health information
will be used and disclosed for this study and describes your rights, including the right to
see your health information. Any information collected about you in this study is
confidential and your name will not be released in any reports or publication without your
expressed consent.
By signing this document, you allow the researcher to use your Personal Health
Information to carry out this Study. This may include information in your medical
records such as medical histories, blood samples, x-rays, physical examinations and any
other data created or collected during the Study.
By signing this document, you also allow the researcher to release your Health
Information to the Institutional Review Board (a group at the University that oversees all
research), the study Sponsor (organization that provides funds for conducting the study)
and any representatives who work on behalf of Sponsor to conduct the Study. Other
persons/investigators directly involved in this study may also receive your Personal
Health Information. Research data sent to the sponsor or other persons does not include
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your name, address, or social security number. Instead, you will be assigned a patient
identification number. Your non-identifiable information may also be given to the U.S.
Food and Drug Administration and other government health agencies around the world
upon their request.
The Sponsor may also reanalyze the results of the study at a later date and combine them
with results of other studies. While using the information in these ways, the sponsor may
give it to its affiliated companies in the US or other countries. The sponsor may also
share the information with its business partners or companies it hires to provide studyrelated services. Again, no identifying information about you will be released at any time
except by an identification number.
The information may be given to the FDA or other government health agencies as part of
applications to gain approval of treatments or to meet other reporting requirements such
as reporting side effects. The results of the study may also be presented to other health
care professionals and published in scientific journals or publications but your identity
will not be disclosed.
You have a right to see and make copies of your medical records.
To ensure the reliability of the Study, however, you agree that you will not be able to see
or copy your records related to the Study until the Sponsor has completed all work related
to the Study. At that time, you may ask to see the Investigator's copy of your medical
records.
You may cancel your authorization at any time.
This authorization to use and disclose your Health Information does not have an
expiration date. You may cancel your authorization at any time by sending a written
notice to the Researcher/Investigator named in this consent at the following address:
The University of Texas at Tyler
Institutional Review Board
c/o Office of Sponsored Research
3900 University Blvd
Tyler, TX 75799
If you cancel your authorization, the Investigator will no longer use or disclose your
Health Information for this Study. However, we are required to record anything that
relates to safety of drugs. I understand the above with regard to my privacy rights.
__________________________________________
___________
Research Participant Signature
Date
__________________________________________
Witness
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Appendix G: Participant Demographic Survey

PARTICIPANT INFORMATION
1. What is today's date?

__________

2. What is the zip code where you live?

__________

3. What is your age?

__________

4. Which of the following best describes your race? (select one item)
1
2
3

American Indian or Alaskan Native
Asian/Oriental or Pacific Islander
Black/African-American

4
5

5. Are you of Spanish or Hispanic origin or ancestry?

1

White/Caucasian
Other

Yes

2

No

6. Which of the following best describes your current marital status? (select one item)
1

Married

2

Widowed

3

Separated

4

Divorced

5

Never married

7. What is the highest grade you completed in school? (select one item)
8th grade or less
2 Some high school
3 High school graduate

Some college
5 College graduate
6 Any post-graduate work

1

4

8. Which of the following best describes your health insurance status?
Employer sponsored insurance
Self-insured
3 Medicaid

Medicare
No insurance (self-pay)
6 Other: _____________________

1

4

2

5

9. Are you currently working?
0
1
2
3
4

No
Yes - Full Time 40 hours per week or more
Yes - Part Time 30-40 hours per week
Yes - Part Time 20-30 hours per week
Yes - Part Time less than 20 hours per week

10. When was your last menstrual period?
1

Within the past month
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Within the last three months
Within the last 6 months
4 Within the last 12 months
5 It has been over 12 months since I have had a period
2
3

11. Which of the following most closely describes your menstrual periods over the past year?
They have a regular pattern, occurring the same time every month (within 6 days)
They are mostly regular but long (>60 days between cycles)
3 They have an irregular pattern and vary by >7 days each month.
4 It has been over 12 months since I’ve had a period.
1
2

12. How old were you when you had your first menstrual period? _______
13. How many times have you been pregnant (write “0” if none)? _______
14. Are you currently pregnant or within 6 weeks of delivery of a baby? Y

N

15. During the past three months, how many minutes on average did you spend exercising per week?
16. How would you best describe your weight over the past year?
My weight has been stable this year (has not changed by more than 5lbs)
I have gained or lost between 5-10 pounds this past year
3 I have gained or lost between 11—19 pounds this past year
4 My weight has changed by over 20 pounds this year
1
2

Do you currently have any of the following conditions? (Select one item for each condition)
17. Cardiac disease

1

Yes

2

No

18. High Cholesterol

1

Yes

2

No

19. Diabetes

1

Yes

2

No

20. High blood pressure

1

Yes

2

No

21. Osteoporosis

1

Yes

2

No

22. Do you smoke?

1

Yes

2

No

Do you currently take any of the following medications? (Select one item for each condition)
23. Estrogen

1

Yes

2

No

24. Progesterone

1

Yes

2

No
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25. Testosterone

1

Yes

2

No

26. Thyroid Medication

1

Yes

2

No

27. Cholesterol Medication

1

Yes

2

No

28. Depression/Anxiety Medication

1

Yes

2

No

*If you answered Yes to any of the above medications please list the name of medication(s) in the space below:

Do you currently take any of the following supplements? (Select one item for each condition)
29. Calcium Supplement

1

Yes

2

No

30. Vitamin D Supplement

1

Yes

2

No

31. Multivitamin Supplement

1

Yes

2

No

32. Are you aware of any ways to reduce abdominal (“belly”) fat in women (other than medications)?
1

Yes

2

If yes, please list:
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Appendix H: Dairy Consumption Questionnaire
Please answer the following questions. Mark one answer for each question.
1. During the past month, approximately how often did you have any dairy milk? (You may include
flavored milk but DO NOT include very small amounts of milk used in coffee or meals)
Never
1-3 times last month
3 1-4 times per week
4 1-2 time per day
5 More than 3 times per day
During the past month, what kind of milk did you usually drink?
1 Whole fat or regular milk
2 2% fat or reduced fat milk
3 1% fat or low-fat milk
4 Fat free, skim, or nonfat milk
5 Other/Not sure/I did not drink dairy milk
During the past month, how often did you eat any kind of cheese? (Including cheese used in foods)
1 Never
2 1-3 times last month
3 1-4 time per week
4 1-2 times per day
5 More than 3 times per day
During the past month, what kind of cheese did you usually eat?
1 Whole fat or regular cheese
2 2% fat or reduced fat cheese
3 Non-fat cheese
4 Other/Not sure/I did not drink eat cheese
During the past month, how often did you eat any kind of ice cream or frozen dairy product?
1 Never
2 1-3 times last month
3 1-4 time per week
4 1-2 times per day
5 More than 3 times per day
During the past month, what kind of ice cream did you usually eat?
1 Regular ice cream
2 2% fat or reduced fat ice cream
3 Non-fat ice cream
4 Other/Not sure/I did not eat dairy ice cream
During the past month, how often did you eat any kind of yogurt?
1 Never
2 1-3 times last month
3 1-4 times per week
4 1-2 times per day
5 More than 3 times per day
1
2

2.

3.

4.

5.

6.

7.
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8. During the past month, what kind of yogurt did you usually eat?
1 Regular, whole milk yogurt
2 2% fat or reduced fat yogurt
3 Non-fat yogurt
4 Other/Not sure/I did not drink eat yogurt
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Appendix I: Daily Yogurt and Dairy Consumption Form
Participant Daily Yogurt Consumption (for Intervention Groups)
Week
#___

Sun

Brand

Type
(Regular,
Greek, etc…)

Flavor
(Plain,
Strawberry,
etc…)

Total
Gm of
Fat

Total
Gm
of
Protein

Total
Ounces
Eaten

Brand

Type
(Regular,
Greek, etc…)

Flavor
(Plain,
Strawberry,
etc…)

Total
Gm of
Fat

Total Gm
of Protein

Total
Ounces
Eaten

Yoplait

Regular

Banana

8 gm

5 gm

6 oz.

Dannon

Greek

Strawb

7 gm

4 gm

6 oz.

Mon

Tues

Wed

Thurs

Fri

Sat

*Frozen Yogurt is not to be included here. If you consume frozen yogurt please count that on the Non-Yogurt form*

Appendix I: Daily Yogurt and Dairy Consumption Form Continued
Participant Daily Non-Yogurt Dairy Consumption* (for Intervention Group)

Week
#___

Sun

Type of Dairy
(Cheese, Milk,
Ice cream
etc…)

Total
Gm of
Fat

Total Gm
of Protein

Total
Ounces
Eaten

Type of
Dairy
(Cheese,
Milk, Ice
cream etc…)

Total
Gm of
Fat

Total Gm
of Protein

Cheese

5 gm

6 gm

2 oz.

Cheese

5 gm

4 gm

Total
Ounces
Eaten

Type of Dairy
(Cheese,
Milk, Ice
cream etc…)

Total
Gm of
Fat

Total Gm
of Protein

Total
Ounces
Eaten

Sour Cream

3 gm

5 gm

3 oz.

Mon
Tues
Wed
Thurs
Fri
Sat
*If more than three servings of different dairy products are consumed during one day you may use additional sheets of paper. If the same item is used more than once
per day you may total those servings together.

Appendix J: Daily Dairy Consumption Form
Participant Daily All-Dairy Consumption* (for Control Group)

Week
#___

Sun

Type of Dairy
(Cheese, Milk,
Ice cream etc…)

Total
Gm of
Fat

Total Gm
of Protein

Total
Ounces
Eaten

Type of
Dairy
(Cheese,
Milk, Ice
cream etc…)

Total
Gm of
Fat

Total Gm
of Protein

Total
Ounces
Eaten

Type of
Dairy
(Cheese,
Milk, Ice
cream
etc…)

Total
Gm of
Fat

Total Gm
of Protein

Total
Ounces
Eaten

Cheese

5 gm

6 gm

2 oz.

Cheese

5 gm

4 gm

1 oz.

Sour
Cream

3 gm

5 gm

3 oz.

Mon
Tues
Wed
Thurs
Fri
Sat

*If more than three servings of different dairy products are consumed during one day you may use additional sheets of paper. If the same item is used more
than once per day you may total those servings together.

Appendix K: Post Study Feasibility Survey

PARTICIPANT INFORMATION What is today's date?

__________

1. Which study group were you assigned to?
1 The FULL-FAT dairy group
2 The NON-FAT dairy group
3 The dairy DOCUMENTATION ONLY group
For participants who were in the FULL or NON FAT dairy groups please
answer the following questions. For those in the DOCUMENTATION ONLY
group skip to question #5.
2. During this study how many times did you FORGET, or chose NOT to consume a
SERVING of yogurt?
1 Zero, I consumed every serving
2 1-3 times
3 3-6 times
4 7-10 times
5 More than 10 times
3. Which statement best describes the most frequent reason why you did not
consume a yogurt serving?
1 I forgot
2 I was not at home
3 I did not feel well
4 I did not feel like eating yogurt
5 Other reason not listed
6 N/A- I consumed all of the servings
4. After completing the study select which of the following statement best fits you?
1 I will consume yogurt every day
2 I will consume yogurt 2-3 times per week
3 I will consume yogurt about once per week
4 I will rarely consume yogurt
5 I will never consume yogurt
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5. During the past three months, how many minutes on average did you spend
exercising per week?

6. Please write any comments that you would like to share with the researcher about
this study:
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